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Proteases play a very important role in a multitude of physiological reactions such
as cell signaling, migration, immunological defense, wound healing and apoptosis and are
crucial for disease propagation. Of the over 400 known human proteases, around 14% are
under investigation as drug targets and the proportion is expected to increase considerably.
The study of proteases and protease inhibitors are emerging with promising therapeutic
uses. In this study we have selected the cysteine and serine protease inhibitor complexes to
understand their inhibition mechanisms. Both proteases share similar catalytic triad
(example: Subtilisin Asp32-His64-Ser221; Papain Cys25-His159-Asn175). Further, the
nature of oxyanion hole found in cysteine proteases of papain super family is similar to that
found in subtilisin. In addition, many of these proteases are secreted as inactive forms
called zymogens and subsequently activated by proteolysis, thereby changing the
architecture of the active site of the enzyme.
This PhD thesis consists of five chapters. Chapter I deals with the literature survey
and general introduction for both cysteine and serine proteases and their inhibitors. Chapter
II deals with the inhibitor complex studies with human cathepsin L. Cathepsin L plays a
vital role in many pathophysiological conditions including rheumatoid arthritis, tumour
invasion and metastasis, bone resorption and remodeling. In this chapter we report a series
of noncovalent, reversible propeptide mimic inhibitors of cathepsin L that have been
designed to explore additional binding interactions with the S’subsites. The design was
based on the previously reported crystal structure that suggested the possibility of
engineering increased interactions with the S’subsites. A few representatives of these new
inhibitors have been co-crystallized with mature cathepsin L, and the structures have been
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solved and refined at 2.2, 2.5, 1.8 and 2.5Å respectively. These four inhibitors were
selected to help clarify and elucidate the binding mode of this class of inhibitors. Of
particular interest was the disposition of the biphenyl groups in the S’ subsites of the
enzyme since the addition of a second biphenyl group to the inhibitor does not improve
potency. These inhibitors described in this work extend farther into the S’subsites of
cathepsins than any inhibitors reported in the literature thus far. These interactions appear
to make use of a S3’subsite that can potentially be exploited for enhanced specificity
and/or affinity. In collaboration with Prof Enrico McGill University, Canada, we have also
carried out molecular dynamics simulations to supplement the information provided by the
crystal structure studies and to explore the dynamical behavior of these inhibitors in the
active site.
Chapter III reports the crystal structure of two covalent dipeptidyl inhibitors in
complex with human Cathepsin-L. These two inhibitors have different groups in S1 subsite
such as inhibitor 1 with α-keto-β-aldehyde and inhibitor 2 with diazomethylketone. The
inhibitor 1 Z-Phe-Tyr (OBut)-COCHO has a Ki=0.6 nM. It is the most potent, synthetic
peptidyl reversible inhibitor of cathepsin L reported to date. The co-crystal structure of this
inhibitor with human Cathepsin-L was refined upto 2.2Å resolution. The inhibitor 2 Z-FY (t-
Bu)-DMK, an irreversible inhibitor which inactivates cathepsin L at μM concentrations has
been co-crystallized and the structure refined upto 1.7Å resolution. These inhibitors have a
substrate-like interaction with the active site cysteine. These structural studies, combined
with our previous complex structures of Cathepsin L reveal the structural basis for the
potency and selectivity of these inhibitors. Our studies on the cathepsin inhibitor complexes
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have the potential leading to further optimization of these inhibitors towards therapeutic
intervention.
Chapter IV deals with serine protease and its inhibitor complex. Serine proteases
play a crucial role in host-pathogen interactions. In the innate immune system of
invertebrates, multidomain protease inhibitors are important in regulating host-pathogen
interactions and antimicrobial activities. Serine protease inhibitors (CrSPI isoforms 1 and
2) of 9.3 kDa were identified from the hepatopancreas of horseshoe crab, Carcinoscorpius
rotundicauda. The CrSPIs were found to be biochemically active, particularly, the CrSPI-1
which potently inhibits subtilisin (Ki=1.43nM). The CrSPI has been grouped with non-
classical Kazal-type inhibitors due to its unusual cysteine distribution. Here we report the
2.6Å resolution crystal structure of CrSPI-1 in complex with subtilisin and its biophysical
interaction studies. The CrSPI-1 molecule consists of two domains arranged in an extended
conformation. These two domains act as two heads to independently interact with two
separate subtilisin molecules resulting in the inhibition of subtilisin activity at a ratio of 1:2
(inhibitor: protease). Each subtilisin molecule interacts with a reactive site loop of CrSPI-1
from each domain through a standard canonical binding mode. We show how such
multidomain inhibitors can simultaneously inhibit multiple enzymes within a single ternary
complex. In addition we propose the substrate preference of the two domains of CrSPI-1.
Domain-2 is more potent and specific towards the bacterial protease subtilisin. Domain-1 is
likely to interact with the host protease, Furin, acting like an “on-off” switch in the
regulation of host’s and pathogen’s proteases. The structure of CrSPI-1-subtilisin ternary
complex will help to understand the innate immune system at a molecular level. Chapter V
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Proteases have long been the centre of attention in biochemistry as models of
enzyme catalysis, structure and also targets for drug development. They make up for
approximately 2% of the gene content in most organisms. It has been estimated that more
nearly 800 different proteases are expressed in the human genome. Their abundance in
nature is only second to transcription factors. Proteases are involved in a multitude of
physiological processes ranging from simple digestion of food to highly regulated
cascades like the blood clotting cascade, apoptosis pathways, complement system, and
the invertebrate prophenoloxidase activating cascade.
1.1 Classification and Nomenclature of Proteases
There are two systems of classifications for proteases – The IUBMB
Nomenclature for Peptidases (EC 3.4) and the MEROPS system. The International
Union of Biochemistry and Molecular Biology (IUBMB) have developed a classification
for enzymes, the EC numbers. Each enzyme is described by a sequence of four numbers
preceded by "EC". The first number broadly classifies the enzyme based on its
mechanism. In this, enzymes have been classified as follows: Oxidoreductases (EC 1),
Transferases (EC 2), Hydrolases (EC 3), Lyases (EC 4), Isomerases (EC 5) and Ligases
(EC 6). Proteases have been assigned to the Hydrolases (EC 3) and further in EC 3.4 - as
those acting on peptide bonds (peptidases). In the EC nomenclature, the classification is
strictly based upon the type of reaction that an enzyme catalyses and this is the basis for
the name of the enzyme. An enzyme is given a unique EC number which can be used as
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an unambiguous reference. Additionally, EC also provides a unique Recommended name
for a protease.
The MEROPS database is an information resource for proteases and
proteinaceous inhibitors. The database is a hierarchical, structure-based classification of
proteases. In this, each protease is assigned to a Family on the basis of similarities in
amino acid sequence, and families that are thought to be homologous are grouped
together in a Clan (group of structurally homologs families).
The MEROPS database classifies proteases based on structural similarity.
Proteases can be roughly classified as Exopeptidases and Endopeptidases based on where
they cleave the substrate proteins (Figure 1.1). Exopeptidases break peptide bonds of
terminal amino acids, in contrast to endopeptidases, which break peptide bonds within the
molecule. Further exopeptidases can be divided as Aminopeptidases (cleave at the N-
terminal end), Carboxypeptidases (cleave at the C-terminal end), Peptidyl Dipeptidases
(cleave 2 residues at C terminal), Dipeptidyl peptidases(cleave two residues at N-
terminal), and Dipeptidases(cleave dipeptides). The EC system uses this system of
classification.
28
Figure 1.1. Classification of proteases based on cleavage specificity.
Figure 1.2. The three levels of classification of proteases (This figure was
adapted from “Proteases New Perspectives” By Vito Turk, Birkhäuser, 1999)
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1.2 Levels of Classification
In the EC and the MEROPS systems, there are three levels of classification for
proteases (Fig 1.2). They are based on the (1) Catalytic types, (2) Molecular structures
and (3) Peptidases. The following sections briefly discuss the details of each level.
1.2.1 Catalytic types
In both EC and MEROPS systems, the major classification is on the basis of the
chemical groups responsible for catalysis i.e. the active site residue. They are serine,
cysteine, aspartic, metallo, and the recently recognized threonine and glutamic acid
proteases. The threonine and glutamic peptidases were not described until 1995 and
2004, respectively. In the serine, cysteine and threonine peptidases, the nucleophilic
attack is carried out by an oxygen or sulphur atom which is part of the protease side
chain. In this case, a covalent acyl enzyme intermediate is formed. This is usually
hydrolyzed but the more N-terminal of the two products of peptide bond cleavage is
transferred from the acyl enzyme to some acceptor other than water. In case of aspartic,
metallo and glutamic peptidases, the attacking nucleophile is a water molecule, bound
and activated in the catalytic site. The functional groups of the protease do not react
directly with the substrate. Hence there are two major catalytic types recognized in the
MEROPS database. The serine, cysteine and threonine peptidases are now classified
under the group – protein nucleophile and the aspartic, metallo and glutamic peptidases
are classified under the group – water nucleophile. In MEROPS, database, the name of
each clan is represented by a single capital letter representing the catalytic type of the
peptidase it contains (S for Serine, T for Threonine, C - Cysteine, A for Aspartic acid, M
for Metallo and U where U stands for unknown type) followed by a letter. The name of a
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family begins with S, T, C, A, M and U, and ends with a number. The letter P is used for
a protein nucleophile clan that contains families of more than one catalytic type. This
system gives an unambiguous reference to a particular family of proteases.
In the EC system, carboxypeptidases and endopeptidases have been subdivided
into the catalytic types as given in Table 1.1. Carboxypeptidase (EC number 3.4.16 -
3.4.18) is an enzyme that hydrolyzes the carboxy-terminal (C-terminal) end of a peptide
bond. Endopeptidases ((EC number 3.4.21 - 3.4.24) are proteases that break peptide
bonds of nonterminal amino acids (i.e. within the molecule), in contrast to exopeptidases,
which break peptide bonds from their terminal ends.
Sub-Subclass Kind of Peptidase
EC 3.4.1 α-Amino-Acyl-Peptide Hydrolases
EC 3.4.2 Peptidyl-Amino-Acid Hydrolases
EC 3.4.3 Dipeptide Hydrolases
EC 3.4.4 Peptidyl Peptide Hydrolases
EC 3.4.11 Aminopeptidases
EC 3.4.12 Peptidylamino-Acid Hydrolases or Acylamino-Acid Hydrolases
EC 3.4.13 Dipeptidases
EC 3.4.14 Dipeptidyl-peptidases and tripeptidyl-peptidases
EC 3.4.15 Peptidyl-dipeptidases
EC 3.4.16 Serine-type carboxypeptidases
EC 3.4.17 Metallocarboxypeptidases
EC 3.4.18 Cysteine-type carboxypeptidases
EC 3.4.19 Omega peptidases
EC 3.4.21 Serine endopeptidases
EC 3.4.22 Cysteine endopeptidases
EC 3.4.23 Aspartic endopeptidases
EC 3.4.24 Metalloendopeptidases
EC 3.4.25 Threonine endopeptidases
EC 3.4.99 Endopeptidases of unknown catalytic mechanism
Table 1.1. Classification of proteases according to EC recommendations
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1.2.2 Molecular Structures
In the level 2 of protease classification, the MEROPS database has classified
peptidases into Families and Clans based on the amino acid sequence similarity and
three-dimensional structure respectively. The database was started in 1993 with all the
available sequences of proteases and subsequently the number of families increased.
Only the sequence identity of portions of proteinases responsible for enzyme activity is
considered for classification of families. Currently the database has 140 families of
proteases. While the peptidase families were being established, it was found that it is not
possible to strictly group proteases based on amino acid sequences as there was evidence
by tertiary structure that some peptidases were related. In evolution, a certain fold is
retained although the amino acid sequence may change. Such distantly related families
of proteases having similar protein folds were termed as Clans. A clan is a group of
families that are thought to have common ancestry. There are about 30 clans in the
MEROPS database. The clans which consist of protein-nucleophile peptidases of more
than one catalytic type are named with a P. The clan of aspartic peptidases is shown as
an example in Fig 1.3.
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Figure 1.3. Clan of Aspartic Peptidases from the MEROPS database (This figure was
adapted from http://merops.sanger.ac.uk/)
1.2.3 Individual Peptidase
At the lowest level of classification are given the criteria to distinguish between
two different peptidases. Two distinct peptidases are expected to meet one of the
following criteria (a) they have different specificities (b) they have different sensitivity
with an inhibitor (c) they belong to different catalytic types or families or (d) they are
encoded by different genes.
The EC system does not explain much about the classification of proteases and it
divides all the proteases into 19 subclasses based on the reactions they catalyse. In
contrast, MEROPS has provided 140 families of proteases grouped into 30 clans with
unique code numbers. Although the EC system does not have a good sytem for the higher
levels of classification, it assigns a unique number to each protease and provides a unique
recommended name for each protease to reduce ambiguity. Hence the EC and MEROPS
together contribute to a sound system of classification of proteases.
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1.3.0 Role of the proteases in diseases
Proteases play important physiological roles and their dysfunction can lead to
pathological states. Organisms use proteases in almost all metabolic processes. The
importance of a few of the well known proteases and their related disorders are
mentioned here. In the digestion of food, the gastric juice secreted in the stomach
contains Pepsins, a class of aspartic proteases functioning in the pH range of 1.5 to 2. The
appearance of pepsin in the oesophagus can lead to proteolytic damage leading to reflux
oesophagitis (Roberts et al., 2006). In the intestine, further breakdown of food is carried
out by serine proteases Trypsin and Chymotrypsin. An inherited autosomal recessive
disorder cystic fibrosis is caused by the deficiency in the transport of Trypsin, a serine
protease secreted by the pancreas. The inability to inhibit Trypsin by its inhibitor
Pancreatic Secretory Trypsin Inhibitor (PSTI) can lead to pancreatitis (Noone et al,
2001). Incomplete protein digestion due to deficiency of chymotrypsin is linked with
autism in children (Malhotra et al., 2002). In the circulatory system, mutations or
disorders of Thrombin, a serine protease involved in many events in blood coagulation,
can lead to Hyperprothrombinemia, cerebral ischemia and infarction (stroke) (Wolberg et
al., 2007). Deficiency in Plasmin, a serine protease in the blood which degrades fibrin
clots may lead to thrombosis. Neutrophil Elastase is an important serine protease
involved in breakdown of bacterial cell walls, if expressed aberrantly causes the lung
disease pulmonary emphysema (Takahashi et al., 1988). Cathepsins, a group consisting
of 11 proteases expressed in all mammalian cells consisting mainly of cysteine proteases
are involved in cellular turnover. Cathepsins have been implicated in Cancer, Stroke,
Alzheimer’s disease, Arthritis, parasite entry and lung diseases (McGrath et al., 1999).
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Caspases a group of 11 cysteine proteases play essential roles in programmed cell death.
Failure of apoptosis is one of the main causes of tumour development while unwanted
apoptosis leads to Alzheimer’s disease (Yuan et al., 2004). Furin, a serine protease
belonging to the Subtilisin-like Proprotein Convertase Family is involved in activation of
hormones. Furin is also utilized used by pathogens like HIV, Ebola, Dengue and Anthrax
viruses for becoming fully functional and gain entry into the host cell (Nakayama et al.,
1998). The ADAM family of metalloproteases is key regulators of cell surface events
and play important functions in vivo for example the development of the heart and the
brain (Hooper et al, 2005).
The projects reported in this thesis are mainly related to serine and cysteine
proteases and their inhibitors. Serine proteases and Cysteine proteases have similar
catalytic triad residues apart from the nucleophilic residue of cysteine or serine which are
histidine and aspartic acid. The mechanisms of catalysis of these two proteases are
similar. In the following section, more details about these two proteases are discussed.
1.3.1 Cysteine proteases
Cysteine proteases are found in all the kingdoms of life. The papain-like cysteine
proteases form the largest subfamily among cysteine proteases. Papain is the archetype of
this family (C1) which belongs to the clan CA Members of this clan has a catalytic triad
composed of a histidine, asparagine or aspartic acid and a nucleophilic cysteine. Papain-
like cysteine proteases are expressed as preproenzymes and are synthesized at the rough
endoplasmic reticulum. Among all the cysteine proteases, the cytoplasmic calpains and
the lysosomal cathepsins (Table 1.3 and Figure 1.4) play the most important
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physiological roles and are implicated in a variety of diseases. Mammalian lysosomal
cysteine proteases play important physiological roles such as in extracellular matrix
turnover, antigen presentation, and processing events and that they may represent viable
drug targets for major diseases such as osteoporosis, arthritis, immune-related diseases,
atherosclerosis, cancer, and parasitic infections(Lecaille et al, 2002). Calpains are non-
lysosomal cysteine proteases found in almost all mammalian and avian cells. Calpains
perform limited proteolysis and are found to activate various kinases and also proteins of
the cytoskeleton. Calpains are thought to be involved in muscle degradation, bone
resorption, formation of cataracts and implicated in several other pathological processes
(Table 1.4). Viral cysteine proteases like 3C proteinase (picornain) being very similar to
chymotrypsin-like serine proteases, have been placed in the mixed category of proteases
(clan PA) as they have evolved from a common ancestor (Otto and Schirmeister, 1997).
Several parasitic protozoan species use cysteine proteases for invasion into host cells, for
example Cruzain used by Trypanasoma cruzi to cause Chagas’ disease. Papain and
Caricain from the papaya plant and Actinidin (from kiwi fruit) are well known plant
proteases.
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Table 1.2. Classification of cysteine proteases (Leung-Toung et al 2006)
Table 1.3 . Members of the Lysosomal Cathepsins. (Adapted from Chemical Reviews,
1997, Vol. 97, No. 1)
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Figure 1.4. Crystal structures of selected proenzyme and mature forms of Cathepsins
Table 1.4. Calpain in Pathological Processes. (adapted from Chemical Reviews, 1997,
Vol. 97, No. 1)
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1.3.2 Catalytic mechanism of cysteine proteases
Fig. 1.5 shows the catalytic mechanism for cysteine proteases having the catalytic
triad Cys-His-Asp/Asn. The catalytic reaction of Cysteine proteases takes place similar to
serine proteases in two phases – (a) acylation and (b) deacylation. In cysteine proteases,
the nucleophilic cysteine residue is already ionized prior to substrate binding. Hence
cysteine proteases can be regarded as a priori activated enzymes. The acylation phase
starts with the deprotonation of the thiol in the enzyme’s active site by the adjacent
histidine residue. In the next step, deprotonated cysteine's anionic sulfur carries out the
nucleophilic attack on the substrate carbonyl carbon forming a tetrahedral transition
state. In the transition state, the carbonyl double bond of the substrate is reformed thereby
breaking the peptide bond between the carbon and nitrogen. The amino portion of the
substrate accepts the hydrogen from the imidazole ring of His, breaking free one part of
the peptide bond with an amino terminal. The histidine residue is released to its
deprotonated form. A thioester intermediate linking the new carboxy-terminus of the
substrate to the cysteine thiol is formed. The -OH portion of the water molecule bonds
with the thioester intermediate forming a second tetrahedral transition state while the
other hydrogen atom bonds with the imidazole ring of histidine. In the next step, the
carbonyl bond of the substrate C-terminal portion is reformed and the bond with the Cys
nucleophilic thiol is broken, thereby freeing the second part of the peptide chain. The
hydrogen bonded to the His is now regained by the Cys thiol. A hydrogen bond is formed
with the Cys and His and thus the active site is regenerated.
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Figure 1.5. The catalytic mechanism of a cysteine protease (Fig adapted from “Enzymes
and their inhibition” By H. J. Smith, Claire Simons, CRC Press, 2005 , ISBN 0415334020)
During the reaction, an oxyanion hole is formed by hydrogen bonding by the sidechain
amide hydrogen atoms of Gln19 and Cys 25 backbone amide hydrogen. This serves to
stabilize the developing negative charge on the carbonyl oxygen atom of the cleaved
peptide. The charge relay involved in cysteine proteases and the oxyanion hole Gln19 are
shown in Fig 1.6.
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Figure 1.6. The catalytic triad of cysteine protease Papain showing the charge relay
involved in making the active site thiol more electronegative.
1.3.3 Inhibitors of Cysteine proteases
The inhibitors of cysteine proteases can be endogenous inhibitors i.e. with a protein
structure or small molecule synthetic inhibitors. The endogenous inhibitors inactivate
cysteine proteases by competitive, noncovalent, reversible inhibition. Some of these
inhibitors also inhibit serine proteases. A number of small molecule synthetic inhibitors
of cysteine proteases are being developed as drugs for various pathological conditions.
These inhibitors are discussed in the sections 1.3.4 and 1.3.5.
.
1.3.4 Endogenous inhibitors: Cystatin superfamily
The endogenous mammalian cysteine protease inhibitors are grouped under the
cystatin superfamily (Otto et al., 1997). These inhibitors are found to be stable at high
temperatures (100° C) and extreme pH and highly specific cysteine protease inhibitors.
Cystatins have been implicated in pathogenic states related to immune responses, cancer
and immune evasion by parasites. There are three families of inhibitor in the cystatin
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superfamily based on sequence homology (a) the cystatins (b) the stefins and (c) the
kininogens. The members of the Stefin family are typically of 11kDa molecular weight
and lack disulphide bridges. Cystatin A and Cystatin B are examples of Stefin family
CPIs. Cystatin A is found mainly in the epithelial cells and neutrophilic granulocytes
whereas Cystatin B is found in all cells and tissues. The Cystatin family has proteins with
typical molecular weight of 12 to 13 kDa. They have two disulphide bridges at the C-
terminal.
Examples are Cystatins C, D, S, SN, and SA. Cystatin C is distributed in the
extracellular space, cortical neurons, in pancreatic islet cells, in the thyroid glands and in
parotid glands. Cystatin S is located in the salivary glands, tear fluid, serum, urine, gall,
pancreas and bronchi. The kininongen family consists of two forms – high molecular
weight kininogens of 120kDa and low molecular weight kininogens of 50-80 kDa.
Kininogens are extracellular proteins. They are also precursors of vasodilatory peptides
kallidin and bradykinin.
1.3.5 Synthetic inhibitors of Cysteine proteases
The low molecular weight inhibitors of proteases in general can be classified as active
site directed or allosteric effectors. Active site directed inhibitors can be further divided
according to the type of interaction into covalent/noncovalent and irreversible/reversible
inhibitors (Table 1.5). Efforts are on to develop small molecule inhibitors of cysteine
proteases for therapeutic purposes. There are several classes of synthetic inhibitors
including peptide aldehydes, methyl ketones and nitriles as reversibly acting inhibitors.
Diazomethanes, halomethyl ketones, acyloxymethyl ketones, O-acylhydroxamates,
epoxysuccinyl derivatives and vinyl sulfones are irreversible inhibitors.
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Table 1.5. Classification of enzyme inhibitors (adapted from Otto and Schirmeister,
1997)
Aldehyde inhibitors are being developed for high selectivity towards
Cathepsins. A drawback of these inhibitors is the high reactivity of the aldehyde moiety.
Tripeptidyl leucine analogues inhibiting cathepsin K have been evaluated in rat adjuvant
arthritis and PTH induced osteoporosis models (Votta et al., 1997). Peptidomimetic
aldehyde inhibitors have been designed to be highly potent and selective to Cathepsin L
and showed in vivo efficacy in a mice model of bone resorption (Yasuma et al., 1998).
By incorporating an α-keto moiety in aldehyde inhibitors, a potent Cathepsin S inhibitor
was designed which has shown efficacy in a murine model of Sjörgen syndrome
(Saegusa et al., 2002). Aldehyde analogues of Vitamin B6 have been developed as potent
inhibitors of Cathepsin B and Cathepsin K and has shown to be effective in an in vitro
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bone resorption assay (Katunuma et al., 1999). Double headed aldehyde inhibitors have
been developed against cysteine and metalloproteases as they have been implicated in
tumor invasion and metastasis (Yamamoto et al., 2002). These have an aldehyde moiety
specific to Cathepsin B and a chelating hydroxamic acid portion for inhibition of matrix
metalloproteases (MMP).
Propeptide mimetic inhibitors have been developed by us for Cathepsin L which
mimics the mode of autoinhibition exhibited by the propeptide region of the proenzyme
of Cathepsin L (Chowdhury et al., 2002). The propeptide regions have been shown to be
potent inhibitors of the mature form of the enzyme. By further optimization of the active
site binding region of the propeptide (Chowdhury et al., 2008) highly potent non covalent
inhibitors have been developed. These inhibitors have a reverse-binding mode i.e. the
backbone of the peptide bond is in the reverse direction as compared to a normal
substrate which makes it resistant to cleavage by the protease. These inhibitors have been
discussed in detail in Chapter II of this thesis.
Acyclic and cyclic ketones were developed in an attempt to reduce the reactivity
of aldehyde inhibitors. In this class, Mercaptomethyl ketones have been designed as
potent and selective inhibitors of cruzipain, a parasitic cysteine protease (Huang et al.,
2001). Conformationally constrained cyclic ketones have been developed as potent and
selective inhibitors of Cathepsin K (Marquis et al., 2001). The introduction of an
azepanone moiety in the cyclic ketone inhibitor increased the potency and bioavailability
and proved efficacious in a nonhuman primate model of osteoporosis (Marquis et al.,
2001). This was the first example of viability of Cathepsin K inhibitors as alternative
treatment of osteoporosis (Stroup et al., 2001).
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Nonpeptidyl derivatives of nitriles having pyrrolidine or azetidine rings have been
found to be potent inhibitors of cysteine proteases. Nitrile inhibitors with 1-
cyanopyrrolidinyl ring were shown to be potent inhibitors of the degradation of
denaturated collagen by cathepsin K and of bone resorption in an in vitro model
(Falgueyret). Dipeptidyl Nitriles have been designed as potent and selective reversible
inhibitors of Cathepsin B (Greenspan et al., 2001).
Epoxysuccinyl analogues are synthetic analogues of the natural product (2S, 3S)-
trans-epoxysuccinyl-L-leucyl-agmatine (E-64), which is a very powerful irreversible
inhibitor of cysteine proteases. Additionally, the propeptide regions of the preproenzymes
are potent inhibitors of cysteine proteases. To mimic the anti-substrate binding mode of
the propeptide of Cathepsin B, an inhibitor was synthesized that contains the dipeptide
moiety Leu-Pro-OH for the P1’-P2’ substrate positions and the tripeptide moiety Leu-
Gly-Gly-OMe for the P2-P4 positions in anti-substrate orientation. This inhibitor was
found to be the most potent among its class (Schaschke et al., 1998). A similar inhibitor
designed for Cathepsin L was effective in reducing tumor-induced hypercalcemia in mice
(Katunuma et al., 1999).
Peptidyl vinyl sulfones are potent irreversible inhibitors of cathepsins. They
have been shown to be effective in mice arthritis models by significantly reducing
inflammation as well as bone and cartilage erosion. They have high potency against
various parasitic cysteine proteases which makes them ideal drug candidates. A vinyl
sulfone inhibitor was demonstrated to cure T. cruzi infections in a mouse model (Engel et
al., 1999). The same inhibitor was found to be orally effective against malaria in mouse
45
model. Preparations are on for the future human clinical trial for Chagas’ disease for this
inhibitor.
Peptidyl diazomethylketones were designed based on the antibiotic azaserine
which inhibits cellular growth by alkylation of a thiol group on the amidotransferase
involved in purine synthesis (Buchanan, 1973). Diazomethylketones were known to be
intermediates in the synthesis of chloromethylketones and also that they did not inhibit
serine proteases. Thus diazomethylketones could be developed as potent, irreversible and
selective inhibitors of cysteine proteases (Shaw, 1984). The first such inhibitor was Z-
Phe-CHN2, an inhibitor of papain (Leary et al, 1977). In chapter III of this thesis, the
crystal structure of Cathepsin-L with a dipeptidyl diazomethylketone inhibitor Z-Phe-Tyr
(t-Bu)-CHN2 is discussed.
Peptidyl α-keto-β-aldehydes or glyoxal inhibitors are potent inhibitors
chymotrypsin, cathepsin B, cathepsin L, cathepsin S, and the proteasome (Lowther et al,
2002). These inhibitors can be synthesized by the oxidative cleavage of the diazogroup of
peptidyl diazomethylketones. α-keto-β-aldehydes have two highly electrophilic carbonyl
atoms as compared to chloromethylketones which have one electrophilic carbonyl and
one alkylating group. They are inhibitors of both serine and cysteine proteases. However
these inhibitors are 10 fold more potent towards cysteine proteases than peptide
aldehydes (Walker et al, 2000). The crystal structure of Cathepsin-L with a dipeptidyl
glyoxal inhibitor Z-Phe-Tyr (t-Bu)-COCHO is discussed in chapter III of this thesis.
β-lactams are well-known compounds as the antibiotic penicillin belongs to this
group. As the drug resistance to antibiotics increased, several β-lactam analogues were
synthesized. Recently reversible β-lactam inhibitors for cysteine proteases have been
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developed. Single ring as well as a bicyclic ring β-lactam moieties have been evaluated as
inhibitors of cysteine proteases. β-lactam analogue inhibitors for Cathepsins K, L, B and
S have been developed(Brömme et al., 2002).
Other classes of inhibitors include Diacyl bis hydrazides which span both the S
and S’ subsites of Cathepsin K and Diamino Pyrrolidinones which are derived by
incorporating a five membered rings in the Diacyl bis hydrazides at the P2 an P2’
positions. Diacyl bis hydrazides have shown efficacy in human osteoclast resorption
assays (Thompson et al., 1997).
1.4 Serine proteases
The serine proteases are named for the nucleophilic Ser residue in their active
sites. The serine proteases have a catalytic triad or charge relay system comprising “Asp-
His-Ser” in their active sites. Almost one third of all known proteases can be classified as
serine proteases. The Asp-His-Ser triad can be found in at least four different clans
(group of structurally homolgous families) of serine proteases - chymotrypsin, subtilisin,
carboxypeptidase Y, and Clp protease which indicate that this catalytic machinery has
evolved on at least four separate occasions (Dodson et al., 1998). The details of these
clans are shown in Table 1.6. This is an example of convergent evolution. Recently,
serine proteases with novel Ser-His-Glu, Ser-Lys/His, His-Ser-His, and N-terminal Ser
catalytic triads and dyads have been discovered (Rawlings et al., 2000). The
Chymotrypsin-like proteases are the most abundant proteases in nature. The
Chymotrypsin family S1 includes intestinal digestive proteins trypsin, chymotrypsin and
also chymase and tryptase found in mast cells, granzymes found in cytotoxic cells and
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thrombin to name a few. Until the sequence and structure of subtilisin was discovered,
Chymotrypsin-like proteases were thought to be the only type of serine proteases. The
subtilisin family S8 is the second largest family of proteases. Most members of this
family are found in bacteria, archaea and fungi and involved in nutrition and some are
pathogenic. Furin, a protease is used by several viruses such as HIV, Anthrax and Ebola
viruses for entry into the host. Subtilisin and Proteinase K are used in the pharmaceutical
industry.
Table 1.6. Clans of Serine proteases classified based on structural similarity in the
MEROPS database. (Table adapted from Chemical Reviews, 2002, Vol. 102, No. 12)
1.4.1Catalytic mechanism of Serine proteases
The catalytic triad or charge relay system of most serine proteases consists of
Asp, His and Ser. Examples are: Asp 102, His 57, Ser 195 in Chymotrypsin , Trypsin and
Asp 32, His 64, Ser 221 in Subtilisin. The Ser side chain –OH group acts as a
nucleophile which attacks the peptide bond. The His imidazole ring, having a pair of
electrons, has the ability to accept hydrogen from Ser. The Aspartic acid carboxyl group
forms a hydrogen bond with His, making the pair of electrons of the His Nitrogen more
48
electronegative and in turn making the nucleophilic Ser Oxygen more electronegative.
The catalytic reaction of serine proteases takes place in two phases – (a) acylation and (b)
deacylation (Carter, 1988; Voet, 1990). The acylation step starts with the Ser side chain
nucleophilic Oxygen attacking the carbonyl group of the scissile peptide bond forming a
tetrahedral transition state. The imidazole ring of His accepts the hydrogen from the Ser
OH and thus acts as a proton acceptor. In the transition state, the carbonyl double bond of
the substrate is reformed thereby breaking the peptide bond between the carbon and
nitrogen. The amino portion of the substrate accepts the hydrogen from the imidazole
ring of His, breaking free one part of the peptide bond. The acylation phase is shown in
Figure 1.7.
Figure 1.7. Acylation reaction in the catalytic mechanism of a serine protease
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Figure 1.8. The deacylation reaction in the catalytic mechanism of a Serine protease
(adaptedfrom http://www.cryst.bbk.ac.uk/pps97)
In the deacylation phase, hydrolysis of the acylated serine residue takes place by the
reaction with a water molecule. The -OH portion of the water molecule bonds with the
acylated serine residue forming a second tetrahedral transition state while the hydrogen
atom bonds with the imidazole ring of histidine. Next, the carbonyl bond of the substrate
C-terminal portion is reformed and the bond with the Ser nucleophilic oxygen is broken,
thereby freeing the second part of the peptide chain. The hydrogen bonded to the His is
now regained by the Ser oxygen and a hydrogen bond is formed with the Ser and His and
thus the active site is regenerated. The deacylation phase is shown in Figure 1.8. In
addition, during the reaction, an "oxyanion hole" is formed by hydrogen bonding by the
backbone amide hydrogen atoms of Gly-193 and Ser-195(in case of Trypsin and
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Chymotrypsin) (Asn 155 and Ser 221 in case of Subtilisin). This serves to stabilize the
developing negative charge on the carbonyl oxygen atom of the cleaved peptide. During
the formation of the tetrahedral transition state, the negative oxygen ion after accepting
the electrons from the carbonyl double bond, perfectly fits into the oxyanion hole. This
makes the tetrahedral transition state more favourable for serine proteases, and increases
the efficiency of the catalytic reaction. The oxyanion hole of serine proteases is shown in
Figure 1.9.
Figure 1.9 The catalytic triad of serine proteases showing the charge relay involved in
making the Ser Oxygen more electronegative.
1.4.2 Serine protease inhibitors
The natural serine protease inhibitors can be classified into three groups – serpins, the
canonical and non-canonical. The serine protease inhibitors have been grouped into
atleast 18 different families (Wlodzimierz et al., 1998). The representative three
dimensional structures of 13 of these families are known. Most of these serine protease
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inhibitors inhibit their cognate enzymes according to a common substrate-like “standard”
mechanism. This group of inhibitors is termed as the canonical inhibitors. They usually
have low molecular weight with around 29 to 190 amino acids (Laskowski et al., 1980).
They all possess an exposed binding loop of a characteristic conformation but are
otherwise not structurally related. The serpins form a family of homologous proteins with
larger molecular weight proteins comprising around 400 amino acid residues (Travis et
al., 1983). They usually have a sugar molecule attached. Serpins also have an exposed
binding loop which interacts with their cognate proteases.
1.4.3 Serpins
Members of the serpin superfamily consist of a core domain of three β-sheets and
8-9 α helices. Although this common fold is found in all serpins, the sequence identity
can be as low as 25%. 16 clades designated A to P have been formed in the superfamily
so far. Serpins are widely distributed among eukaryotes and viruses that infect them.
They have not been found in fungi but a bacterial serpin was recently discovered (Irving
et al, 2002). Serpins are abundantly found in the human plasma and most of them are
inhibitors of thrombin. Others are inhibitors of coagulation proteins Factor Xa, Factor
XIa or of fibrinolytic proteinases like plasmin. The gene knock-out of the serpin
antithrombin has proven to be lethal in mice. Serpins are found in many highly regulated
physiological processes, such as blood coagulation, fibrinolysis, and inflammation (Stein
et al., 1995). Some important serpins are α1-PI (Schulze et al., 1994), α2-
antiplasmin(Wiman et al., 1978), C1 inhibitor(Bock et al., 1986), and neuroserpin(Davis
et al., 1999) . Serpins are found in four different conformations - metastable state, latent
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state, cleaved state and the δ state. From the latent state, the serpins fold into a metastable
state, and subsequently undergo insertion of the
Figure 1.10. Comparison of the four different conformations of the serpin α1-proteinase
inhibitor (adapted from Gettins, 2002)
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reactive loop into β-sheet A, and form a covalent serpin-proteinase complex. Thus serpins
undergo dramatic change in their conformations in the reactive site loop (Figure 1.10)
unlike the rigid mode of inhibition in canonical binding inhibitors discussed in the
following section.
1.4.4 Canonical serine protease inhibitors
The binding loop or reactive site loop residues P3-P3’ serve as a recognition motif
which, depending on the sequence inhibits a particular protease (Lee et al, 2007). The P1
residue located in the center of the loop is responsible for most of the interactions with
the protease and binds to the S1 specificity pocket of the protease. The binding loop
mode of interaction with the protease is similar to a substrate. Usually a short antiparallel
β-sheet is formed between the P3-P1 residues and the 214–216 (chymotrypsinogen
numbering) segment of the enzyme. An important feature is a short contact (about 2.7Ǻ)
between the P1 carbonyl carbon and the catalytic serine residue and two hydrogen bonds
between carbonyl oxygen of P1 and Gly193/Ser195 amides. The conformation of the
binding loops of different families is similar, which is an example of convergent
evolution. The canonical inhibitor families include BPTI (Kunitz) family, Kazal family,
STI family(Soybean Trypsin Inhibitor or STI-Kunitz family), SSI family(Streptomyces
Subtilisin Inhibitor), Potato inhibitor 1 family, Potato inhibitor 2 family, Chelonianin
family, Bowman-Birk family and Squash seed inhibitors family. Selected members of
the families are shown in Figure 1.11.
The crystal structure and the canonical binding mode of a Kazal inhibitor, CrSPI-
1 with its cognate protease Subtilisin has been discussed in detail in Chapter III of this
thesis.
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Figure 1.11. Representative structures of selected canonical serine protease inhibitor
families. BPTI (BPTI family), Eglin C (Potato Inhibitor 1 family), Squash seed inhibitor
1(Squash seed inhibitor family), Mung bean trypsin inhibitor(Bowman-Birk family),
Turkey ovomucoid third domain( Kazal family), Mucous proteinase inhibitor(
Chelonianin family) Fig adapted from Bode and Huber, Eur J Biochem, 1991
55
1.4.5 Non canonical serine protease inhibitors
The Hirudin family of serine protease inhibitors bind in the noncanonical mode to
the cognate protease (Folkers et al, 1989). Hirudin is an inhibitor of thrombin isolated
from the leech and binds according to a very different mechanism. Hirudin’s globular
domain contacts surface patches adjacent to the thrombin active site. The extended C-
terminal tail of hirudin runs in a long groove extending from the active sit cleft of
thrombin to the positively charged putative fibrinogen binding exosite, thereby making
several hydrophobic contacts and surface salt bridges. This non-canonical interaction
may be used more frequently in serine proteinase inhibition, but has so far been defined
only for hirudin.
1.4.6 Synthetic inhibitors of serine proteases
The irreversible inhibitors of serine proteases can be grouped as alkylating agents,
acylating agents, phosphonylating agents, and sulfonylating agents based on the
mechanism of inhibition (Powers et al., 2002) . Alkylating agents include fluoromethyl
ketones, chloromethyl ketones, acyloxymethyl ketones, epoxides, aziridines, vinyl
sulfones, and other Michael acceptors. Acylating agents include β-lactams, lactones, aza-
peptides, and heterocyclic derivatives. Phosphonylating agents include peptide
phosphonates and phosphonyl fluorides. Several fluorescent derivatives of phosphonate
esters have been used for cellular localization of serine proteases. Phosphonyl fluorides
are very potent inhibitors of serine proteases and esterases. Phosphonyl fluoride inhibitors
such as diisopropyl phosphonofluoridate (DFP), isopropylmethyl phosphonofluoridate
(Sarin), and 1,2,2-trimethylpropylmethyl phosphonofluoridate (Soman) are nonselective
toward a particular serine protease. Sulfonylating agents include Sulfonyl fluorides.
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Sulfonyl fluorides inhibit most serine proteases such as chymotrypsin, trypsin, elastase,
complement, coagulation, and fibrinolytic serine proteases. Examples are PMSF and 4-
(2-aminoethyl) benzenesulfonyl fluoride. Several irreversible inhibitors have been tested
for the possible therapeutic application. For instance inhibitors such as β-lactams and
saccharins are the inhibitors of neutrophil elastase for the treatment of emphysema. A
number of other bioavailable or orally active inhibitors are now available including
benzoxazinones and saccharins as inhibitors for elastase and viral proteases and vinyl
sulfones. Several inhibitors are undergoing clinical trials, including a γ-lactam inhibitor
that is being tested in trials for inflammatory disorders. A thrombin inhibitor is being
developed for use as a surgical glue by an Atlanta biotechnology company. Thrombin can
be acylated by trans-cinnamoyl active esters to give stable acyl enzyme derivatives.If the
cinnamoyl group has an o-hydroxy group, then it can easily be deacylated
photochemically regenerating active thrombin. This led to the concept of “surgical glue”,
which is being developed by Porter and co-workers. The acyl thrombin derivative can be
applied to any desired surgical site and then activated with a laser. The tissue gets glued
together when “fibrin” is generated by Thrombin.
The serine and cysteine proteases have similar catalytic mechanisms involving a charge
with respect to the active site nucleophile, the histidine and the oxyanion hole. The
following chapters of this thesis report the co crystal structures and mechanism of
inhibition of Cathepsin-L and Subtilisin with their inhibitors. The major objective of this
thesis is to elucidate the structure based mechanism of inhibition of a cysteine protease
i.e. human Cathepsin-L and a serine protease Subtilisin using potent reversible and
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irreversible inhibitors. X-ray crystallographic approach is used as a primary method
throughout. Structure based drug design is the most powerful method for design of
inhibitors for various targets involved in disease states. The X-ray crystallographic data
shows at an atomic level how a drug or an inhibitor interacts with the target protein which
will contribute immensely to the development of better inhibitors. Chapter II describes
the inhibition of Cathepsin-L by a series of propeptide mimetic inhibitors. The aim of this
work is to enhance the potency of retrobinding inhibitors by increasing the interactions in
the S' subsites of Cathepsin-L. In this chapter, interactions made by four inhibitors from
this series are described in detail. To supplement the crystal structure data, the dynamic
behavior of these inhibitors and electrostatic preferences are also studied by using
Molecular Dynamics simulations in collaborations with Prof Enrico, McGill University
Canada. In chapter III the co-crystal structures of Cathepsin-L with two covalent
inhibitors- a peptidyl diazomethyl ketone and a peptidyl glyoxal inhibitor are described.
These inhibitors have identical peptide sequences and differ only in the reactive group
which modifies the active site thiol. This study helps to explain the structural basis for the
difference in potency of these two inhibitors. Finally, chapter IV outlines the crystal
structure of the serine protease Subtilisin in complex with a Kazal-type inhibitor from the
horseshoe crab, Carcinoscorpius rotundicauda. This double headed kazal inhibitor
inhibits two molecules of subtilisin i.e. captures one molecule of subtilisin with each of
its domains. Isothermal Titration Calorimetry has been used to supplement the dynamics
of binding of this inhibitor to subtilisin. Synthetic peptides derived from the reactive site
loop residues of the inhibitors have been tested for their inhibition. These studies will
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further advance our knowledge on the innate immune defense mechanism of arthropods
and also provide a basis for design of antibacterials and endotoxin detection.
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Chapter II




The papain superfamily of cysteine proteases consists of numerous members
among which Cathepsins form the largest group. In humans, 11 Cathepsins are known to-
date (McGrath, 1999). The main function of these cathepsins is the terminal protein
degradation in the lysosome. Although mainly being scavengers in the lysosome, they
play vital physiological roles like in bone resorption and remodelling, T-cell maturation,
prohormone processing and apoptosis (Li et al., 2009). Recent studies have shown the
involvement of Cathepsins in several pathological conditions like tumour invasion and
metastasis, osteoporosis, arthritis, atherosclerosis, emphysema, muscular dystrophy,
parasitic infections and cancer (Sheahan et al., 1989; Esser et al., 1994; Turk et al., 2001;
Joyce et al., 2004). Cathepsin L is an important member of this group which has been
implicated in tumour growth and invasion. Therefore Cathepsin L has been recognized as
viable targets for therapeutics and cysteine proteases in general are attractive targets for
drug design.
Cathepsin L is biosynthesized as an autoinhibited zymogen with a 96-residue
propeptide segment that spans across the entire active site cleft completely blocking
access to it. The direction of the propeptide backbone is reversed as compared to the
substrate binding mode, conferring resistance to hydrolysis. We have reported a series of
non-covalent retro-binding inhibitors designed to span the S–S' regions of the active site
of Cathepsin L that mimic the propeptide binding mode (Chowdhury et al., 2008;
Chowdhury et al., 2002). These inhibitors showed nanomolar potency and high
selectivity for Cathepsin-L. The first crystal structure of such an inhibitor (pdb code
1mhw) confirmed the reverse-binding noncovalent nature of inhibition. However, this
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inhibitor contained a Cys amino acid that, during co-crystallization, caused the inhibitor
to dimerize through disulfide bond formation (Chowdhury et al., 2002). The resulting
bound conformation placed the biphenyl rings from each monomer in the S' subsites of
the protein. This raised some uncertainty as to the nature of the protein-ligand
interactions in the S' subsites for the monomeric inhibitor.
In this chapter we report the second crystal structure of a member of this class of
inhibitors containing an S-benzyl Cys derivative that precluded dimer formation (pdb
code 3bc3). The binding mode of the inhibitor at the S1 to S3 subsites was identical to
that previously reported for the dimeric form. However, the interactions of the biphenyl
groups in the S’ subsite were significantly different between the two crystal structures. In
addition this chapter reports the crystal structures of three more inhibitors that have been
selected to help clarify and elucidate the binding mode of this class of inhibitors. Further,
in collaboration with Prof Enrico, McGill University Canada, we have carried out
molecular dynamics simulations to supplement the information provided by the crystal
structure studies.
2.2 Experimental
Inhibitor synthesis and enzyme assay was performed in the collaborator’s lab. The
chemical diagram of the inhibitors and their binding affinities are shown in Table 2.1a.
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Table 2.1a. Inhibitor Structures co-crystallized with Cathepsin-L and their activities.
2.2.1 Co-crystallization and Data collection
Inhibitor 2: The mature cathepsin L was inhibited with inhibitor 2 by incubating the
protein and inhibitor in the presence of 2 mM DTT at room temperature for 3 h. Protein
was stored in a buffer of 20 mM sodium acetate at pH 5.7, 100 mM NaCl, and 1 mM
EDTA. Because of the limited solubility of the inhibitor, approximately 0.01 mM
concentration of protein and inhibitor were initially mixed to obtain a final ratio of 1:3 M
63
(protein: inhibitor). After incubation, the complex was gradually concentrated up to 14
mg/mL. Crystals of the complex were grown by the hanging drop vapor diffusion method
at room temperature with a reservoir solution of 17% (w/v) polyethylene glycol 8000
(PEG 8K) and 0.2 M ammonium sulfate.
Inhibitor 4: The complex of Cathepsin L with inhibitor 4 was prepared by incubating the
protein with inhibitor in the presence of 2 mM DTT at room temperature for 3 hours.
Protein was kept in 20 mM Sodium acetate pH 5.7, 100 mM NaCl, and 1mM EDTA. Due
to the limited solubility of inhibitor 0.01M concentration of protein and inhibitor, that is
dissolved in 25% DMSO, were used to prepare the initial mixture with a final ratio of 1:4
M (protein : inhibitor). After incubation the complex was subsequently concentrated up
to 9 mg/ml. Crystals of the complex were grown after 10 days by the hanging drop vapor
diffusion method at room temperature with a reservoir solution of 19%(w/v) polyethylene
glycol 8000 and 200mM Ammonium sulfate.
Inhibitor 9: The complex of Cathepsin L with inhibitor 9 was prepared by following the
above mentioned procedure to a ratio of 1:5 M (protein: inhibitor) and concentrated up to
10 mg/ml. Crystals of the complex were grown after 3 weeks by the hanging drop vapor
diffusion method at room temperature with a reservoir solution of 25%(w/v) polyethylene
glycol 8000 and 200mM Ammonium sulfate.
Inhibitor 14: The complex of Cathepsin L with inhibitor 14 was prepared by following
the above mentioned procedure to a ratio of 1:5 M (protein: inhibitor) and concentrated
up to 15 mg/ml. Crystals appeared after 2-3 weeks by the hanging drop vapor diffusion
method at room temperature with a reservoir solution of 30%(w/v) polyethylene glycol
8000 and 200mM Ammonium sulfate.
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All the co-crystallization drops were composed of 1 μl of reservoir solution and
1μl of the complex. We have also soaked all the crystals to ensure the inhibition of
Cathepsin L in the crystals by the addition of 1.5μM respective inhibitors solution into
the drop. Diffraction data sets were collected on an R-axis IV + + area detector mounted
on RU300 rotating anode detector and / or on a synchrotron beam line, BNL, with 25%
glycerol as cryo-protectant.
2.2.2 Structure Solution and Refinement
Initial phases for Cathepsin L inhibitor complexes were obtained by molecular
replacement method with Molrep and using the mature cathepsin L coordinated taken
from Procathespin L (PDB code 1CS8) (Vagin and Teplyakov, 1997). The initial R-factor
was 42% for all the complexes and subsequent refinement was carried out with CNS
(Brünger et al., 1998). Resulting model with the electron density map was examined and
the model was fitted with the O program (Jones et al., 1991). Omit maps were calculated
for positioning the inhibitor molecules. All four model buildings and refinements were
carried out using O and CNS programs with appropriate entries in their respective
dictionaries. Overall geometry of final models was analyzed by PROCHECK (Laskowski
et al., 1993). The data collection and refinement statistics are provided in the Table 2.1b
and Table 2.2.
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2.3 Results and Discussion
2.3.1 Structure of inhibitor 2 and Cathepsin L complex
The crystal structure of mature human cathepsin L complexed with inhibitor 2
was determined at 2.2 Å resolution. Compound 2 inhibits mature cathepsin L with a Ki of
0.155 μM. The asymmetric unit consists of two inhibitor complex molecules. The
structure was solved by the molecular replacement method using mature cathepsin L
coordinates derived from procathepsin L (PDB code 1CS8). The model has been refined
with good stereochemical parameters. Statistics for the Ramachandran plot from an
analysis using PROCHECK19 for the inhibitor complex model gave 84.5% of nonglycine
residues in the most favored region (Table 2.1b). Electron density of the mature cathepsin
L residues from Thr175 to Gly179 is not observed and is presumably disordered.
Figure 2.1 shows the simulated annealing Fo - Fc omit map for the substrate-
binding region of the cathepsin L inhibitor 2 complex. The inhibitor molecule is well-
defined in the electron density map. As predicted, similar to the proregion, the crystal
structure of this inhibitor complex adopts noncovalent and reverse substrate-binding
mode of inhibition. The electron density around the active-site Cys25 side chain indicates
the possibility of oxidized sulfur. There are 10 direct hydrogenbonding contacts (<3.2 Å)
between the bound inhibitor and the mature cathepsin L of the complex.
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Root mean square deviation
Bond length (Å) 0.006








Main chain atoms 28.41




Waters (no. atoms) 40.3 (395)
Ligand (no. atoms) 27.90 (12)
a Rsym = |Ii -<I>|/ |Ii| where Ii is the intensity of the ith measurement, and <I> is
the mean intensity for that reflection.
b Rwork = | Fobs - Fcalc|/ |Fobs| where Fcalc and Fobs are the calculated and observed
structure factor amplitudes, respectively.
c Rfree = as for Rwork, but for 8.5% of the total reflections chosen at random and
omitted from refinement.
d Individual B-factor refinement were carried out.
* Reflections greater than I>cI where used in the refinement
67
Figure 2.1. Simulated-annealing Fo - Fc omit map in the active-site region of the
cathepsin L inhibitor complex. Inhibitor molecule and all atoms within 3 Å from the
inhibitor molecule were omitted prior to refinement. The map is contoured at a level of
2σ. This figure was prepared using Bobscript (Esnouf, 1999).
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The overall binding mode of inhibitor 2 is comparable to that of the dimeric form
of inhibitor 1 with D-Arg anchored at the S1 subsite and the Tyr and phenylethyl groups
at the S2 and S3 subsites, respectively, in essentially identical orientations.18 The major
differences lie in the orientation of the biphenyl rings (Figure 2.2).
Figure 2.2. Overlay of the 1MHW crystal structure (cyan carbon chain) and the crystal
structure of 2 (green carbon chain).
In the current structure, the biphenyl group starts out in S2′ but projects into S3′in an 
orientation perpendicular to the biphenyl in the dimeric part of inhibitor 1 (PDB code
1MHW). The orientation of the S-benzyl group follows the chain of the disulfide bond in
1MHW and positions the center of the benzene ring near the CR of Cys in the second
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monomer. These results suggest that the positioning in S2′of the biphenyl rings of the 
first half of the inhibitor dimer in 1MHW was induced by the presence of the dimer and
that the preferred position for the monomer is at S3'. These findings motivated us to
determine the structures of remaining complexes, in particular inhibitor 4. It is interesting
to see the crystal structure of inhibitor 4, which is a close mimic of the dimer, and once
again displace the first biphenyl toward the S2'-binding site (please see the section on
Inhibitor 4).
The diaminoketone inhibitors of cathepsin K also have substantial interactions
with the S'-binding sites. In Figure 2.3, we aligned the cathepsin K structure (PDB code
1AU0) with the cathepsin L structure in this work and display and overlay of the
cathepsin K inhibitor and molecule 2 in the cathepsin L active site. The diaminoketone
inhibitor has Cbz-Leu occupying the S′subsites. We see that the Cbz group roughly
overlaps with the first half of the biphenyl group of 2 and that Leu side chain occupies
part of the region used by the S-benzyl group.
Figure 2.4 shows a similar alignment for a vinylsulfone inhibitor (PDB code
1AU2).15 The phenyl rings of the inhibitor overlap with part of the biphenylacetyl group
of 2, and the sulfone S atom is positioned similarly to the S-benzyl sulfur of 2. However,
neither the diaminoketone nor vinylsulfone inhibitors reach as far as the second ring of
the biphenyl group of 2. These molecules represent three different classes of inhibitors
that make significant interactions with the S′subsites of cathepsins. Of these classes, the 
inhibitors in this work make the most extensive use of the putative S3′subsite.
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Figure 2.3. Overlay of 2 with a diaminoketone inhibitor (PDB code 1AU0).
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Figure 2.4. Overlay of 2 with a vinylsulfone inhibitor (PDB code 1AU2).
2.3.2 S3' Subsite
Many years ago, Schechter and Berger suggested the existence of seven subsites
in papain spanning S4-S3' based on hydrolysis data on a series of polyalanine peptides.
However, there is no direct structural evidence for the existence of all these subsites.
More recently, Turk and co-workers have revised the definition of substrate-binding sites
in cysteine proteases to S3-S2' based on the available crystal structures of inhibitors and
substrate analogues. In their analysis, they see a S1'- and S2'-binding site but no evidence
for S3'. The crystal structure in the present work reveals a binding site on cathepsin L that
extends far beyond the S2' subsite. Of course, this is a crystal structure of an inhibitor,
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and there is no evidence that a substrate would actually use the extended binding site.
However, the proximity of the binding site to S2' makes it a reasonable binding site for a
P3' side chain. Figure 2.5 shows a manually generated polyalanine peptide overlaid onto
the crystal structure of inhibitor 2. We see that there is the potential for the P3' side chain
to make use of the extended subsite. Hence, the region around the second ring in the
biphenyl of 2 plausibly suggests a putative S3' subsite.
Figure 2.5. Overlay of 2 with a hypothetical polyalanine substrate.
2.3.3 Electrostatics of the S1' Subsite
In the vicinity of the S1' binding is a negatively charged Asp162. In particular, the
distance between the sulfur atom of S-benzylcysteine and one of the carboyxlate oxygens
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of Asp162 is 4.4 Å. This raised the possibility of designing an inhibitor with a positively
charged moiety occupying S1' to interact with the carboxylate of Asp162. To explore the
electrostatic preferences at the S1' subsite, three inhibitors (10, 11, and 12) containing
neutral, positive, and negative groups for binding at S1' were synthesized and tested. In
these inhibitors, the Cys in 1 was replaced by aminobutyric, reported in other charge
selectivity calculations in the literature, this value is relatively small. This suggests that
although the S1' subsite prefers a neutral group it does not have a strong preference for
one.
2.3.4 Design of dimer-mimetic propeptide inhibitors
The previously described design and synthesis of inhibitors 4 and 9, which were
inspired by the crystal structure of inhibitor 1 (pdb code 1mhw) (Chowdhury et al., 2008;
Chowdhury et al., 2002). In that structure, inhibitor 1 had inadvertently dimerized
through a disulfide bond and positioned two biphenyl groups in the S' subsites of
cathepsin L. Inhibitors 4 and 9 were designed to mimic the interactions seen in the
inhibitor 1 crystal structure. These inhibitors contain a second biphenyl group without the
additional bulk of a second monomer (Table 2.1a). This was accomplished by attaching a
biphenylacetyl group to Nε of a Lys side chain in the inhibitor. However, neither 4 nor 9
exhibited improved binding affinity compared to 14, the most potent compound in the
congeneric series.8 In order to understand the lack of improved potency; we solved the
crystal structures of 4, 9 and 14.
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2.3.5 Structure of the dimer-mimetic propeptide inhibitor complexes
The structure of mature human cathepsin L complexed with inhibitors 4, 9 and 14
was solved by using rotating anode and / or synchrotron data sets, and refined up to 2.5,
1.8 and 2.5 Å resolution, respectively. The structures were determined by the molecular
replacement method using mature cathepsin L coordinates taken from the procathepsin L
pdb (pdb code 1cs8). Each of the models has been refined with good stereochemical
parameters (Table 2.2). Statistics for the Ramachandran plot from an analysis using
PROCHECK for the three models gave over 83% of non-glycine residues in the most
favored regions, and no residues in the disallowed region. Electron density corresponding
to the residues Thr175 to Gly179 of mature Cathepsin L is not observed and is
presumably disordered. The inhibitor molecules are well defined in the electron density
maps. The inhibitors occupy the active site in a noncovalent and reverse-binding mode of
inhibition. The overall structure of mature cathepsin L resembles that of mature part of
the proenzyme. Thus we will not provide any details of the mature cathepsin L structure.
2.3.6 Inhibitor 4
The binding mode of inhibitor 4 in the S1 to S3 subsites is similar to that seen in previous
crystal structures of this class of inhibitors (Figures 2.6 and 2.7). The Arg residue of the
inhibitor is located in S1 with its side chain solvent exposed and its backbone carbonyl
making a hydrogen bond with the NH group of Gly68.
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In the S2 subsite, the inhibitor Tyr side chain has nonpolar interactions with Leu69,
Met70 and Ala135 and its amide NH forms a hydrogen bond with the Gly68 carbonyl.
The N-(2-6 phenylethyl)-amide group packs against the Gly68 main chain and the side
chain of Leu69. Inhibitor 4 makes fairly extensive interactions with the S' subsites. The
Nε-biphenylacetyl modified Lys side chain is in a fairly extended conformation in the S'
region. The distance from the Lys Cα to the carbon at the tip of the biphenyl group is
15.6Å. The biphenyl rings of the Nε-biphenylacetyl-Lys side chain interact with the side
chains of Glu141, Phe145 and somewhat more distantly with Leu144. The acetyl
methylene group interacts with Cα of Gly139. The Lys side chain methylene groups pack 
against the protein surface. The amide group of the Nε-biphenylacetyl-Lys side chain
forms a hydrogen bond with the carbonyl of Ala138. In the S2' subsite, the 4-
biphenylacetyl rings makes hydrophobic interactions with the side chain of Leu144. The
carbonyl oxygen of the biphenylacetyl group makes a hydrogen bond with the indole
nitrogen of Trp189. Figure 2.8 shows the simulated annealing Fo-Fc omit map for
inhibitor 4.
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Figure 2.6. Stereo view of interactions between the inhibitor 4 and cathepsin L. Protein
atoms are shown in thin lines whereas the inhibitors are shown in thick lines. The figure
was prepared using PyMOL (DeLano Scientific, Palo Alto, CA)
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Figure 2.7. Schematic view of cathepsin L interactions with inhibitor 4. The Figure was
prepared using LIGPLOT (Wallace et al, 1995)
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Figure 2.8. Stereo view of the simulated annealing Fo-Fc omit map in the active site
region of cathepsin L. The bound inhibitor 4 and all atoms within 3Å of the inhibitor
molecule were omitted prior to refinement. The map is contoured at a level of 2σ for
inhibitor 4. The figure was prepared by using PyMOL (DeLano Scientific, Palo Alto,
CA).
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Examination of the crystal packing contacts revealed that the S' regions of two adjacent
protein molecules face each other and create a shared binding cavity at the interface that
subsequently gets occupied by parts of the inhibitors bound to each protein unit. The
biphenyl rings of the inhibitor bound to one protein interact with the biphenyl rings of the
other inhibitor bound to the other protein (Fig 2.9). The Nε-biphenyl of one protein is
packed between the backbone biphenyl and the Gln21 side chain of the other
Figure 2.9. Crystal packing interactions of two adjacent protein-ligand complexes in the
unit cell of Inhibitor 4 and cathepsin L complex
protein. It is thus possible that the bound conformation of the inhibitor in the S' subsites
in this crystal structure may not be representative of that found in an isolated protein-
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ligand complex in solution. Binding in the S subsites, however, does not seem to be
affected by the crystal packing.
2.3.7 Inhibitor 9
The binding mode of inhibitor 9 in the S1 to S3 subsites is essentially the same as
that seen for inhibitor 4 (Figures 2.10 and 2.11). D-Arg is found in the S1 subsite with the
side chain guanidium group exposed to solvent and backbone carbonyl hydrogen bonded
to the Gly68 amide. The Phe side chain makes nonpolar interactions with the side chains
of Leu69, Met70 and Ala135 in the S2 subsite. In the S3 subsite, the NH group of the N-
(2-phenylethyl)-amide makes a direct hydrogen bonding contact with the main chain
carbonyl oxygen of Gly68. The phenyl ring of the N-(2-phenylethyl)-amide group packs
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Figure 2.10. Stereo view of interactions between the inhibitor 9 and cathepsin L. Protein
atoms are shown in thin lines whereas the inhibitors are shown in thick lines. The figure
was prepared using PyMOL (DeLano Scientific, Palo Alto, CA)
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Figure 2.11. Schematic view of cathepsin L interactions with inhibitor 9. This figure
was prepared using LIGPLOT (Wallace et al, 1995)
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against the backbone atoms of Gly68 and the side chain of Leu69. The orientation of the
Nε-biphenylacetyl-Lys side chain in the S' subsites is very similar between inhibitors 4
and 9 but the position of the other biphenylacetyl group is significantly different in the
two structures. As with inhibitor 4, the rings of the Nε- biphenylacetyl-Lys side chain
interacts with the side chains of Glu141, Leu144 and Phe145. The amide group of the Nε-
biphenylacetyl-Lys makes a direct hydrogen bond with the carbonyl of Ala138. Unlike
inhibitor 4, the other biphenylacetyl group does not appear to have extensive interactions
with the protein. Its main points of contact are nonpolar interactions with the backbone
and side chains of Gln21.
As in inhibitor 4, examination of the symmetry related contacts revealed that the
S’ regions of two adjacent proteins face each other. The backbone biphenyl from one
inhibitor stacks against the side chain biphenyl from the other inhibitor (Fig 2.12). It is
possible that the binding mode in the S’ sites is not representative of that in the isolated
complex in solution. The binding in the S subsites appears unaffected by the crystal
packing interactions. Figure 2.12 shows the simulated annealing Fo-Fc omit map for the
inhibitor 9. In inhibitor 4 the electron density of the inhibitor backbone biphenyl is
somewhat weak and even more so in inhibitor 9. This suggests that this group is highly
mobile and may be fluctuating between the two positions represented in the two crystal
structures.
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Figure 2.12. Stereo view of the simulated annealing Fo-Fc omit map in the active site
region of cathepsin L. The bound inhibitor 9 and all atoms within 3Å of the inhibitor
molecule were omitted prior to refinement. The map is contoured at a level of 2.5σ for
inhibitor 4. The figure was prepared by using PyMOL (DeLano Scientific, Palo Alto,
CA).
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Figure 2.13. Crystal packing interactions of two adjacent protein-ligand complexes in the
unit cell of Inhibitor 9 and cathepsin L complex.
2.3.8 Inhibitor 14
Inhibitor 14 is a close analog of inhibitor 1, the first compound in this class that
was crystallized (pdb code 1mhw). The main difference is the replacement of Cys by S
methylCys (or MCys, for short). This precludes the formation of a disulfide-bridged
dimer as occurred in the crystallization of inhibitor 1. This inhibitor represents the
original design of this class of compounds. The binding mode of inhibitor 14 at the S1–
S3 subsites is essentially the same as that of inhibitors 4 and 9 and will not be discussed
further (Figures 2.14 and 2.15). In the S1' subsite, the MeCys makes nonpolar
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interactions with the side chain of Ala138. The 4-biphenylacetyl group is found to be in a
conformation different from inhibitors 4 and 9 and is in a very extended conformation
reaching towards putative S3' subsite (Fig 2.14) discussed previously. The biphenyl group
stacks against Trp189 and interacts with Gln21 on the other face of the rings. At the
farthest tip of the biphenyl group there is some contact with the Cαof Trp193. The
simulated annealing Fo-Fc omit map for inhibitor 14 shows that the position of the
biphenyl rings is reasonably well-defined (Fig 2.16). Unlike in the crystal structures of
inhibitors 4 and 9, examination of crystal packing interactions in the structure of inhibitor
14 do not show significant interactions between inhibitors from different symmetry
related protein molecules. However, there is a symmetry-related interaction between the
side chains of corresponding Leu144 residues that modifies the binding surface near the
inhibitor biphenyl rings (see below),
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Figure 2.14. Stereo view of interactions between the inhibitor 14 and cathepsin L.
Protein atoms are shown in thin lines whereas the inhibitors are shown in thick lines. This
figure was prepared using PyMOL (DeLano Scientific, Palo Alto, CA)
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Figure 2.15. Schematic view of cathepsin L interactions with inhibitor 9. The figure was
prepared using LIGPLOT (Wallace et al, 1995)
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Figure 2.16. Stereo view of the simulated annealing Fo-Fc omit map in the active site
region of cathepsin L. The bound inhibitor 14 and all atoms within 3Å of the inhibitor
molecule were omitted prior to refinement. The map is contoured at a level of 2σ for
inhibitor 4. The figure was prepared by using PyMOL (DeLano Scientific, Palo Alto,
CA).
In the section 2.3.1 of this chapter we have discussed the crystal structure of
inhibitor 2 (pdb code 3bc3), a close congener of 14. A comparison of the bound
conformations of the two inhibitors shows a similar binding mode with the biphenyl rings
extended towards the putative S3’ binding site and the biphenyl rings stacked against the
Trp189 rings. However, in the crystal structure of 2 the biphenyl ring overlaps more with
the Trp189 rings and comes close to the Phe145 side chain. In the crystal structure of 14 a
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symmetry-related interaction between side chains of corresponding Leu144 residues
occludes the region between Trp189 and Phe145, altering the binding mode of the
biphenyl group relative to that seen in the crystal structure of 2. In order to explore how
the binding modes might change in the absence of crystal packing interactions, in
collaboration with Prof Enrico, McGill University, Canada, the molecular dynamics
simulations were run as described in the next section.
2.3.9 Molecular Dynamics
Molecular dynamics simulations of cathepsin L protein complexed with 4, 9, and
14 were carried out in order to further clarify the binding mode of the inhibitors.
Trajectories of 12 ns were generated for each of the inhibitors. Figure 2.17 shows plots of
the time series of selected distances describing the positions of S’-binding groups of 4.
The S’-binding moieties of 4 were highly mobile during the first half of the simulation
before finally settling down to a reasonably stable conformation. The time series of the
distance between C4 of the backbone biphenyl (see Figure 2.7 for ligand atom
numbering) and the CG atom of Trp184 is shown in Figure 2.17a. The backbone biphenyl
group fluctuates significantly during the first 6 ns and then ends up packing against the
Trp184 indole ring. The side chain biphenyl is even more mobile during the first 6 ns
before finally packing against the backbone biphenyl. The side chain Nε-biphenyl C62
carbon and the backbone biphenyl C4 ranged from 10-12 Å apart for much of the first 6
ns before coming together to a distance of about 5 Å (Figure 2.17b). The lysine side chain
Nε of 4 is initially hydrogen bonded to the Ala138 carbonyl O and remains so for the first
half of the simulation (Figure 2.17c).
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Figure 2.17. Interatomic distance fluctuations involving inhibitor 4. (a) Trp184 Cγ –
Inhibitor C4, (b) Inhibitor C4 – inhibitor C62 (biphenyl-biphenyl interaction), (c) Ala138
carbonyl O – Inhibitor Lys Nε. See Figure 2.7 for atom numbering of inhibitor 4.
The hydrogen bond is eventually broken as the two biphenyl groups come together. The
Nε remains in a fairly stable position for the remainder of the simulation. Figure 2.18
shows a similar time series for selected distances describing the positions of S’-binding
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groups of inhibitor 9. The evolution of the distance between the C4 of the backbone
biphenyl (see Figure 2.11 for ligand atom numbering) and the CG atom of Trp184 is
shown in Figure 2.18a. The backbone biphenyl group quickly settles down after less than
100 ps and then ends up packing against the Trp184 indole ring. The side chain Nε-
biphenyl group is much more mobile than its counterpart in 4 and does not end up
packing against the other biphenyl group (Figure 2.18b). At the end of the 12 ns
simulation, it hasn’t really settled down to a defined binding site. This is consistent with
the lower binding affinity observed for 9 as compared to 4 and 14. Also unlike in 4, the
lysine side chain Nε of 9 manages to maintain hydrogen bond to the Ala138 carbonyl O
for most the 12 ns trajectory (Figure 2.18).
In contrast to 4 and 9, the binding mode of 14 was quite stable throughout the 12-
ns simulation. Figure 2.19 shows time series of the distance between the C4 carbon of the
backbone biphenyl and the CG atom of Trp184. It remains stable at around 4.5 Å
throughout the 12 ns. The position of the MCys side chain also remains stable
throughout. The MD-refined structure of 4 suggests a possible explanation for its lack of
improved potency compared to 14 despite the addition of an extra biphenyl group to
interact with the S’ subsites of cathepsin L. Figure 2.20 shows a snapshot towards the end
of the trajectory that is representative of the final ensemble of conformations. The side
chain biphenyl seems to form largely intramolecular interactions with the backbone
biphenyl.
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Figure 2.18a. Interatomic distance fluctuations involving inhibitor 9. (a) Trp184 Cγ –
Inhibitor C4,
Figure 2.18b Interatomic distance fluctuations involving inhibitor 9. Inhibitor C4 –
inhibitor C62
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Figure 2.18c. Interatomic distance fluctuations involving inhibitor 9. (c) Ala138
carbonyl O – Inhibitor Lys Nε. See Figure 2.11 for atom numbering of inhibitor 4.
Figure 2.19. Interatomic distance fluctuations involving inhibitor 14. Trp184 Cγ –
Inhibitor C4. See Figure 2.15 for atom numbering of inhibitor 14.
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Figure 2.20. Snapshot of MD-refined structure of inhibitor 4.
The diminished intermolecular interactions together with the larger entropic cost of
restricting many rotatable bonds of the Nε- biphenylacetyl-lysine group leads to no net
gain in binding affinity compared to 14. Perhaps forming a macrocyclic structure instead
of two independent biphenyls would reduce the entropic cost and result in improved
potency.
2.4 Conclusion
In this chapter we have reported the crystal structures of four inhibitors in
complex with mature cathepsin L. Through this work, we have established the binding
conformation of the monomeric form of our retro-binding peptidomimetics. The
conformation at the S1-S3 subsites was essentially identical to that previously reported
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for the dimeric form. However, the disposition of the biphenyl group at the S’subsites
was significantly altered. We explored extending the inhibitor to increase interactions
with the S'subsites. Although these extensions appear to be well-accommodated, they do
not confer enhanced binding affinity, perhaps because of increased entropic costs upon
binding. The electrostatic preferences at the S1' subsite were also analyzed. A neutral
group is slightly preferred at S1'. Further to explore the S’ subsite, we have selected three
more inhibitors to help clarify and elucidate the binding mode of this class of inhibitors.
Of particular interest was the disposition of the biphenyl groups in the S’ subsites of the
enzyme since the addition of a second biphenyl group to the inhibitor does not improve
potency. Due to some question about the effects of symmetry-related interactions in the
crystal, we have also carried out molecular dynamics simulations to supplement the
information provided by the crystal structure studies and to explore the dynamical
behavior of these inhibitors in the active site. After the MD simulations, all three
inhibitors have one biphenyl group packing against the Trp189 rings. In inhibitor 4, the
second biphenyl packs against the first one. In inhibitor 9, the second biphenyl group is
highly mobile and does not appear to have a highly preferred binding site. The behavior
of these inhibitors in the MD simulations is qualitatively consistent with the
experimentally observed potencies of these inhibitors. Overall the inhibitors (especially
inhibitor 2) described in this work have the most extensive interactions with the
S'subsites of cathepsins reported in the literature thus far. These interactions are highly




Crystal Structures of Human Cathepsin L
Complexed with a Peptidyl Glyoxal Inhibitor
and a Diazomethylketone Inhibitor
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3.1 Introduction
Cathepsin L a member of the cysteine proteases of the papain superfamily is
responsible for the the breakdown of proteins in the lysosomes and plays an important
role in antigen processing, tumour invasion and metastasis (Tomssen et al, 1995) and
bone resorption (Kakegawa et al, 1993). The catalytic triad of Cathepsin-L consists of
Cys25, His163 and Asn187. The substrate binding cleft of Cathepsin L has six binding
pockets and denoted as S3, S2, S1, S1’, S2’, and a putative S3’ identified in Schechter
and Berger annotation (Schechteri & Berger, 1967). These subsites are located along the
catalytic cleft between the left (L) and right (R) domains of Cathepsin L. The unprimed
subsites S1, S2 and S3 bind the N terminal of the substrate or inhibitor whereas the
primed subsites accommodate the C-terminal part of the substrate. The substrate
specificity of Cathepsin L is determined by the presence of an amino acid with a large
hydrophobic side chain at the P2 position (Shaw et al, 1993). Cathepsin L cleaves
substrates near bulky aromatic residues which bind to subsites S2 and S3 (Kirschke et al,
1988).
Synthetic inhibitors of cysteine proteases are composed of two parts. The first part
is the peptidyl fragment which interacts with the binding pockets. This peptidyl fragment
has a protecting group like Carboxybenzyl, tosyl (T) or t-butoxycarbonyl (Boc)
(Janowski et al, 2004). The sequence of the peptidyl group is usually derived from
natural protease inhibitors like human cystatins and E64, a natural irreversible inhibitor
of cysteine proteases (Grubb et al, 1990). The second part of the synthetic inhibitors of
cysteine proteases consists of the reactive group to interact with the active site. This
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reactive site group includes aldehydes, nitriles, azapeptides, halomethylketones,
diazomethylketones, and their intermediates like α-keto-β-aldehydes. There are several
classes of compounds are known to inhibit cathepsin L, including diazomethyl ketones,
acyloxymethyl ketones, epoxysuccinyl derivatives (such as E-64) and peptidyl aldehydes,
such as leupeptin and peptide α-keto β-aldehydes (Powers et al, 2002).
Diazomethylketones have been developed for cysteine proteases such as papain,
cathepsins B, C, H, L, and S, calpain, streptopain, and clostripain (Schroder et al, 1993).
Peptidyl diazomethylketones have been shown to be effective against lysosomal cysteine
proteases due to their ability to penetrate cells of various types. Leupeptin and, a peptide
aldehyde and epoxide inhibitors have been used for the inhibition of cysteine proteases.
However they lack selectivity and inhibit a wide range of cysteine proteases. The
inhibitor Z-Phe-Tyr (t-Bu)-CHN2 inhibits Cathepsin-L selectively and irreversibly with
an inhibition constant in the range of 10-8 M. This inhibitor is over 104 times more
effective for Cathepsin L than Cathepsin S (Shaw et al, 1993). It inhibits Cathepsin L
with a rate 2.5 x 104 times greater than that for cathepsin B.
Similarly peptidyl α-keto-β-aldehydes or glyoxal inhibitors are potent inhibitors
of chymotrypsin, cathepsin B, cathepsin L, cathepsin S, and the proteasome (Lowther et
al, 2002). These inhibitors can be synthesized by the oxidative cleavage of the
diazogroup of peptidyl diazomethylketones. α-keto-β-aldehydes have two highly
electrophilic carbonyl atoms as compared to chloromethylketones which have one
electrophilic carbonyl and one alkylating group. They are inhibitors of both serine and
cysteine proteases. However these inhibitors are 10 fold more potent towards cysteine
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proteases than peptide aldehydes (Walker et al, 2000). The Z-Phe-Tyr (OBut)-COCHO is
a slow, tight-binding reversible inhibitor of cathepsin L with a Ki=0.6 nM and is the most
potent Cathepsin-L inhibitor reported to date (Lynas et al, 2000).
The structure of Cathepsin L in complex with E-64, a natural irreversible inhibitor
from Aspergillus japonicus has been previously reported (Fujishima et al, 1997).
Cathepsin L in complex with propeptide-mimetic reverse binding non-covalent inhibitors
has been studied extensively (Chowdhury et al, 2002). The design of these inhibitors is
based on the propeptide region of Procathepsin-L, which is a potent inhibitor of its
mature form. So far, there has been no crystal structure reported for any glyoxal inhibitor.
As a continuation of our studies on human Cathepsin L, in this chapter we report the
crystal structure of Cathepsin L in complex with a diazomethyl ketone inhibitor and a
glyoxal inhibitor. This study has the potential to develop potent and selective inhibitors of
cathepsin L towards therapeutic intervention.
3.2 MATERIALS AND METHODS
3.2.1 Crystallization and data collection
Z-Phe-Tyr (OBut)-COCHO complex: The human Cathepsin L was expressed in the
methylotrophic yeast Pichia pastoris and purified as described previously (Coulombe et
al, 1996). Z-FY (t-Bu)-DMK and Z-Phe-Tyr(OBut)-COCHO were purchased from
Calbiochem. Cathepsin L was kept in a buffer consists of 20 mM Sodium acetate pH 5.1,
100 mM NaCl, and 1mM EDTA. The inhibitor was dissolved in 25% DMSO. Due to the
limited solubility of inhibitor, initial concentration of protein and inhibitor were kept at
0.01M. The complex of mature Cathepsin L with inhibitor Z-Phe-Tyr (OBut)-COCHO
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was prepared by incubating the protein with inhibitor (1:4 molar ratio) in the presence of
2 mM DTT at room temperature for 3 hours. After incubation the complex was
subsequently concentrated up to 15 mg/ml. Initial crystallization condition was obtained
from the Hampton Research Screens (Cudney et al, 1994). Diffraction quality crystals of
the complex were grown after 2 days by the hanging drop vapor diffusion method at
room temperature with a reservoir solution consists of 15 % w/v PEG 8000 and 200 mM
Ammonium Sulfate. A hexagonal shaped crystal was obtained with a space group P65
, a=85.55, b=85.55, c= 50.20 Å. These crystals diffracted to a maximum resolution of
2.2 Å. A complete data set was collected using the frozen complex crystal at the
Beamline X29A, National Synchrotron Light Source, Brookhaven National Laboratories,
USA (Shi et al, 2006).
Z-FY (t-Bu)-DMK: Cathepsin L complex: The Cathepsin L : Z-FY(t-Bu)-DMK inhibitor
complex was prepared following the same procedure as above and concentrated up to 15
mg/ml. The initial crystallization condition was derived from Hampton Research
Screens. The diffraction quality crystals were appeared after 2 days by the hanging drop
vapor diffusion method at room temperature with a reservoir solution consists of
30%(w/v) polyethylene glycol 8000 and 200mM Ammonium sulfate. These crystals were
belongs to hexagonal form and diffracted up to 1.7Å with space group P65 and unit cell
parameters a=85.55, b=85.55, c= 50.20 Å. X-ray diffraction data were recorded at 100 K
at X29A beamline at the Brookhaven National Laboratories, Upton, New York, USA.
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3.2.2 Structure Solution and Refinement
The structure of Cathepsin L inhibitor complexes were solved by molecular
replacement method using Molrep (Vagin & Teplyakov, 1997). Mature cathepsin L
coordinates from Procathepsin L (PDB code 1CS8) was taken as a search model. The
initial R-factor was 41.1% and 44.5% for inhibitor 1 and inhibitor 2 complexes
respectively. Subsequent refinement was carried out with Refmac (Murshudov et al,
1997), which reduced the R-factor to 22% and 24% respectively. At this stage the
calculated difference electron density map was examined and the inhibitors were
modeled using the O program (Jones et al, 1991). Further refitting and alternated with
refinements were carried out using O and CNS (Brunger et al, 1998) programs with
appropriate entries in their respective dictionaries. Overall geometry of final model of
both inhibitor complexes were analyzed by PROCHECK (Laskowski et al, 1993).
Crystallographic statistics and refinement details are provided in Table 3.1.
3.3 Results and Discussion
The structure of human Cathepsin L in complexed with (1) Z-Phe-Tyr(OBut)-
COCHO (hereafter referred as inhibitor 1) and (2) Z-FY(t-Bu)-DMK (hereafter referred
as inhibitor 2) were determined by the molecular replacement method from synchrotron
data sets. Both complexes were refined to final R-factors of 19.9% and 20.4%
(Rfree=23.1% and 24.9%) at 1.7 and 2.2Å resolutions respectively. The refined models
have good stereochemical parameters (Table 3.1). There is one complex molecule per
asymmetric unit of both crystals. The mature Cathepsin L of both inhibitor complexes is
very similar and they superimpose with an rmsd of less than 1Å for all Cα atoms. Further
the mature cathepsin molecule is identical to the previous complexes as well as the
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mature portion of the procathepsin L crystal structure (pdb code 1cs8). Thus we will not
discuss the details of the mature Cathepsin L structure. In both complex structures the
inhibitors are bound to the active site Cys25 by a covalent bond. In addition the inhibitor
molecules are tightly held in the substrate binding pockets through several hydrogen
bonding and hydrophobic interactions.
3.3.1 Z-Phe-Tyr (OBut)-COCHO : Cathepsin-L complex: This structure reveals that
the β-aldehyde forms a tetrahedral thiohemiacetal(Fig 3.1a) with the α-ketone oxygen
atom facing towards the Cathepsin L oxyanion hole. The inhibitor sidechains fit well in
the S subsites as opposed to S’ subsites of Cathepsin L. The aldehyde moiety of Z-Phe-
Tyr (OBut)-COCHO is covalently attached to the Cys25 thiol group forming a
thiohemiacetal. The Tyr (O-But) group occupies the S1 pocket of Cathepsin-L, which is
relatively wide and unrestricted. The phenyl and carboxybenzyl group of the inhibitor
occupy hydrophobic pockets on opposite faces of the substrate binding cleft in the S2 and
S3 subsites respectively (Figs 3.1b, 3.1c).
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Figure 3.1a Chemical reaction between Z-FY(t-Bu)-COCHO(inhibitor 1) and
Cathepsin L.
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Table 3.1. Crystallographic data and refinement statistics
Z-FY(t-Bu)-DMK Z-Phe-Tyr(OBut)-COCHO
Space group P65 P65
Cell parameters (Å, º) a = 85.56, b = 85.56, c =
50.20 α= 90 β=90  γ=120
a = 85.56, b = 85.56, c =
50.20 α= 90 β=90  γ=120
Resolution range (Å) 50-2.2 50-1.8
Wavelength (Å) 1.000 1.000
Observed hkl 208669 164173
Unique hkl 22014 10156
Completeness (%) 95 (55.4) 95.1 (75.7)
Overall I/σI 9.9 5.5
aRsym 0.057(0.55) 0.117(0.52)
Refinement and quality of the model
*Resolution range 50-1.70 (1.76-1.7) 50-2.2 (2.28-2.2)
bRwork (%) no. reflections 19.9 (16998) 20.4 (7382)
cRfree (%) no. reflections 23.1 (1434) 24.9 (678)
Root mean square deviation
Bond length (Å) 0.107 0.009
Bond angle (º) 1.54 1.34
Ramachandran plot (%)
Favored region 85.3 83.2
Allowed regions 14.1 16.3
Generously allowed region 0.5 0.5
Disallowed regions 0 0
dAverage B-factors (Å2)
Main chain atoms 23.37 33.82
Side chain atoms 26.29 36.11
Overall protein atoms (no.
atoms)
24.774 (1706) 34.9 (1706)
Waters (no. atoms) 52.1 (190) 54.9 (136)
Ligand (no. atoms) 23.90 (38) 39 (39.2)
a Rsym = |Ii -<I>|/ |Ii| where Ii is the intensity of the ith measurement, and <I> is the mean
intensity for that reflection. b Rwork = | Fobs - Fcalc|/ |Fobs| where Fcalc and Fobs are the
calculated and observed structure factor amplitudes, respectively. c Rfree = as for Rwork,
but for 8.5% of the total reflections chosen at random and omitted from refinement. d
Individual B-factor refinement were carried out.
* Reflections greater than I>σI where used in the refinement
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There are six hydrogen bonding contacts between inhibitor 1 and the substrate
binding cleft of Cathepsin L. In the S1 pocket, the backbone amide of Tyr (OBut) group
makes a hydrogen bond with the carbonyl oxygen of Asp162 (3.12Å). The hydroxyl
group of the β-aldehyde oxygen donates a proton to the Nδ1 imidazole ring of His163
which is a part of the catalytic triad of Cathepsin-L. There are two contacts in the S1
subsite made by the α-keto carbonyl oxygen – two with the backbone amides of Ser24
and Cys25 (2.73 and 2.54Å respectively). The Carboxybenzyl group fits well into the S3
pocket. This group makes two hydrogen bonding contacts with the S3 subsite. The
backbone carbonyl oxygen of the inhibitor involves in a hydrogen bonding contact with
the amide of Gly68 (2.87Å). Moreover the N-terminal amide of the inhibitor forms a
hydrogen bond with the carbonyl oxygen of Gly68 (3.0Å). The interactions made by the
inhibitor are shown in Figures 3.2a and 3.2b.
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Figure 3.1b. Crystal structure of the molecule showing inhibitor 1 in the active site of
Cathepsin L displayed in surface representation. This figure and the following figures of
this chapter were prepared using PyMol (DeLano Scientific, Palo Alto, CA)
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Figure 3.1c. Crystal structure of the molecule showing inhibitor 1 in the active site of
Cathepsin L displayed in cartoon representation.
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Figure 3.2a. Interactions made by inhibitor 1 in the catalytic cleft of Cathepsin L.
Inhibitor 1 is shown in magenta and Cathepsin L residues are shown in green. This figure
was prepared using PyMol.
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Figure 3.2b. Schematic view of cathepsin L interactions with inhibitor 1. The Figure
was prepared using LIGPLOT (Wallace et al, 1995)
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It was previously proposed that inhibitor 1 (Z-Phe-Tyr (OBut)-COCHO) forms a
transition state thiohemiketal tetrahedral adduct similar to the transition state tetrahedral
adduct formed during substrate catalysis in Cathepsin L (Lynas et al, 2000). It has been
shown by NMR experiments (Lowther et al, 2002) that the high potency of the glyoxal
inhibitor Z-Phe-Ala-glyoxal against papain is due to the high reactivity of the β-aldehyde
group and not due to the formation of a thiohemiketal tetrahedral adduct. The complex
structure presented here is the first crystallographic evidence which proves this concept.
Figure 3.3 shows the final electron density map for the substrate binding site region of
this inhibitor complex which clearly shows that the inhibitor Z-Phe-Tyr (OBut)-COCHO
forms a thiohemiacetal with active site Cys25 of Cathepsin L. Moreover the ketone
carbonyl group of the inhibitor molecule is not in a position to engage a nucleophilic
attack with the thiol group of Cys25.
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Figure 3.3. Final 2Fo-Fc electron density map for the inhibitor 1 and its covalent
attachment to Cys25 of Cathepsin L. The figure was prepared using Pymol.
In the S1’ subsite of the substrate binding cleft, the tert-Butyl group involves in
hydrophobic interactions with the sidechains from Leu144, Trp189, Ala138 and Gly139.
Notably, Trp189 forms a part of the aromatic cluster of Cathepsin L along with Trp193,
and Phe143. Similarly in the S2 subsite, the phenyl sidechain has non-polar interactions
with the sidechains of Leu69 and Met70. The tert-butyl group is a bulky substituent
usually used for kinetic stabilization and can cause a reaction rate acceleration by a factor
of 240 compared to hydrogen as a substituent (Cauwberghs et al, 1988). In addition the
P3 sidechain Carboxybenzyl has hydrophobic interactions with the aliphatic part of
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Glu63 sidechain. The selected hydrogen bonds and hydrophobic interactions are listed in
Table 3.2a and 3.2b.
Table 3.2a: Hydrogen bonds(Å) formed by Inhibitor 1 in the catalytic cleft of Cathepsin
L
Inhibitor 1 atom Cathepsin L atom Distance(Å)
Phe O15(O) Gly 68 N 2.87
Phe N33 (N) Gly 68 O 3.00
Tyr N18(N) Asp 162 O 3.12
Tyr O22(O) Ser 24 N 2.73
Tyr O22 (O) Cys 25 N 2.54
Tyr O23(O) His 163 Nδ1 2.71
Table 3.2b: Hydrophobic contacts between Inhibitor 1 and Cathepsin L binding pockets
Inhibitor 1 atom Cathepsin L atom Distance(Å)
t-Butyl C26(C) Leu 144 Cδ1 3.86
t-Butyl C26(C) Gly 139 Cα 3.84
t-Butyl C6(C) Ala 138 Cβ 3.73
t-Butyl C7(C) Trp 189 Cζ2 3.65
Phe C10(C) Leu 69 Cδ2 3.84
Phe C11(C) Leu 69 Cδ2 3.68
Phe C11(C) Met 70 Cε 3.76
Phe C11(C) Ala 135 β 3.85
3.3.2 Z-Phe-Tyr (t-Bu)-DMK : Cathepsin L complex: The inhibitor molecule Z-Phe-
Tyr (t-Bu)-DMK is covalently bound to the Cathepsin L active site Cys25 by a thioester
bond i.e. the methylene of the diazomethane group is covalently attached to the Sγ atom
of Cys25(Fig 3.4a). As seen in the glyoxal inhibitor (inhibitor 1) complex structure, the
Tyr (t-Bu) group, phenyl group and the Carboxybenzyl group of the inhibitor occupies
the S1, S2 and S3 subsites (Fig 3.4b and 3.4c). A total of five hydrogen bonding contacts
between the inhibitor molecule and the substrate binding cleft of Cathepsin L are
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observed. The carbonyl oxygen of the inhibitor is pointing towards the oxyanion hole of
Cathepsin L comprising
Figure 3.4a Chemical reaction between Z-FY(t-Bu)-diazomethylketone(inhibitor 2) and
Cathepsin L.
of Gln19 and Cys25. Further this forms hydrogen bonding contacts with the sidechain
amide of Gln19 and the backbone amide of Cys25. In the S1 subsite, the backbone amide
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of the Tyr (t-Bu) group makes a hydrogen bond with the carbonyl oxygen of Asp162. It is
noteworthy that in the S3 pocket, there are two hydrogen bonding contacts between the
backbones of the inhibitor Phenyl group and the Gly68 of Cathepsin-L, which introduces
an anti-parallel β-sheet. Previously similar antiparallel β-sheet formation has been
reported for papain diazomethylketone complex (Janowski et al), papain
chloromethylketone complex (Drenth et al, 1976), and papain leupeptin complex
(Schroder et al, 1993). The selected hydrogen bonding contacts are listed in Table 3.3a.
The t-Butyl group of the tyrosine sidechain of the inhibitor forms a part of the
hydrophobic cluster which consists of the sidechains from Trp189, Leu144 and Ala138 in
the S1’ subsite. Similarly in the S2 subsite, the Phenyl group sidechain of the inhibitor
molecule has non-polar interactions with the sidechain of Leu69 and Ala135. Further in
the S3 subsite, the Carboxybenzyl group has hydrophobic interactions with the aliphatic
part of the sidechain Glu63. The selected hydrophobic interactions are listed in the Table
3.3b. The interactions made by inhibitor 2 are shown in Figures 3.5a and 3.5b and the
final 2Fo-Fc electron density map are shown in Figure 3.6.
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Figure 3.4b. Crystal structure of the molecule showing inhibitor 2 in the active site of
Cathepsin L displayed in surface representation. The figure was prepared using Pymol.
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Figure 3.4c. Crystal structure of the molecule showing inhibitor 2 in the active site of
Cathepsin L displayed in cartoon representation. The figure was prepared using PyMol.
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Figure 3.5a. Interactions made by inhibitor 2 in the catalytic cleft of Cathepsin L.
Inhibitor 2 is shown in yellow and Cathepsin L residues are shown in green. The figure
was prepared using Pymol.
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Figure 3.5b. Schematic view of cathepsin L interactions with inhibitor 2. The Figure
was prepared using LIGPLOT (Wallace et al, 1995)
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Figure 3.6. Final 2Fo-Fc electron density map for the inhibitor 2 and its covalent
attachment to Cys25 of Cathepsin L. The figure was prepared using Pymol.
Table 3.3a: Hydrogen bonds (Å) formed by Inhibitor 2 in the catalytic cleft of Cathepsin
L.
Inhibitor 2 atom Cathepsin L atom Distance(Å)
Tyr O3(O) 19 Gln (Nε2) 2.97
Tyr O3(O) 25 Cys (N) 3.08
Phe O28 (O) 68 Gly (N) 2.92
Phe N36 (N) 68 Gly (O) 2.97
Tyr N38 (N) 162 Asp (O) 3.16
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Table 3.3b: Hydrophobic contacts between Inhibitor 2 and Cathepsin L binding pockets
Inhibitor 2 atom Cathepsin L atom Distance(Å)
t-Butyl C4(C) Trp 189 Cη2 3.64
t-Butyl C7(C) Leu 144 Cδ1 3.65
t-Butyl C7(C) Ala 138 C 3.97
t-Butyl C7(C) Gly 139 Cα 3.77
Cbz C16(C) Glu 63 Cδ 3.82
Phe C23(C) Leu 69 Cδ2 3.62
Phe C24(C) Ala 135 Cβ 3.70
The superposition of the crystal structures (Figure 3.7) of the two inhibitor
complexes shows that the overall conformations of the two inhibitors are similar. There is
high congruity between the Carboxybenzyl, Phenyl and Tyr (t-Bu) groups. The only
difference is found in the reactive groups which form the covalent bond with the active
site Cys25 of the Cathepsin L. The geometry of the covalent link between the inhibitor
molecule and the cathepsin L is different in the two complexes. In both complex
structures, the tertiary butanol group makes similar hydrophobic interactions with
sidechains of the residues in the S’ site of Cathepsin-L. The antiparallel β-sheet formed
between the Gly68 and the inhibitor Phenyl group is a feature seen in both the inhibitor
structures as well as in other Cathepsin-L complexes like chagasin-cathepsin complex
and cruzipain complex (Ljunggren et al, 2007). This β-sheet formation is possible due to
the flexibility of Gly68 in this region of Cathepsin L. Although the hydrophobic
interactions between the two inhibitor molecules are similar, the glyoxal inhibitor
(inhibitor 1) makes 2 additional hydrogen bonds compared to the diazomethylketone
inhibitor (inhibitor 2). It was previously speculated that P’ hydrogen-bonding interactions
between active site residues and the hydrated β-aldehyde hydroxyl group of the α-keto-β-
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aldehyde group are crucial for the effectiveness of this inhibitor (Lynas et al, 2000).
From our crystal structure we found that there are no P’ hydrogen bonding interactions
between the inhibitor molecule and the hydrated β-aldehyde hydroxyl group.
Figure 3.7. Overlay of crystal structures of Cathepsin L complexes with inhibitors 1 and
2. Inhibitor 1 is shown in magenta and inhibitor 2 is shown in yellow. The figure was
prepared using PyMol.
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In fact, it forms a hydrogen bond with the catalytic triad residue His163 in the S1
pocket. Moreover the carbonyl oxygen of the α-keto group is involved in two hydrogen
bonds i.e. with Ser24 and Cys25 whereas in case of the diazomethylketone inhibitor, the
carbonyl oxygen of the inhibitor makes two hydrogen bonding interactions i.e. with the
oxyanion hole residues Gln19 and Cys25. These unique interactions in inhibitor 1 may
be crucial in explaining the higher potency of the glyoxal inhibitor.
Gln19 is conserved among all known cysteine proteases and is an important
feature of the catalytic mechanism of cysteine proteases. The mutation of Gln19 leads to
a 60-600 fold decrease in the activity of papain (Ménard et al, 1995). When papain is
inhibited by an aldehyde inhibitor, a tetrahedral transition state similar to that found in
substrate catalysis is formed (Menard et al, 1991). But in this inhibitor complex, the
oxyanion hole Gln19 is not utilized as it forms a neutral tetrahedral transition state. In the
case of a substrate, the Gln19 is utilized because there is a charge transfer between Cys25
and carbonyl oxygen of the substrate. Hence the catalytic machinery used for charge
stabilization will not be used in all compounds reacting with the enzyme. In our present
study of the α-keto β-aldehyde inhibitor, Gln19 is not utilized because the tetrahedral
hemithioacetal is a neutral group in which there is no charge transfer. But in the case of
diazomethyl ketone inhibitor (inhibitor 2), there is a hydrogen bonding contact with the
Gln19 which implies that the oxyanion hole is utilized as the formation of the thioester
with Cys25 involves the removal of the electrophilic diazogroup. It is evident that
different types of inhibitors utilize the catalytic machinery of Cathepsin L differently as
has been observed in the case of papain (Dufour et al, 1995). Aldehydes are potent
inhibitors of cysteine proteases. The potency of these inhibitors is suggested to be due to
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the formation of covalent adducts similar to the tetrahedral transition state of substrate
catalysis. In the case of inhibitor 2, the diazomethylketone inhibitor complex, the carbon
atom of the thioester bond has sp2 hybridization and adopts a trigonal geometry (Figure
3.8). This is a comparatively slower reaction compared with inhibitor 1. The structure of
the complex formed with inhibitor 2 resembles the acyl enzyme intermediate than the
tetrahedral hemithioacetals formed between cysteine proteases and their transition state
intermediates. In inhibitor 1, similar to a transition-state intermediate, Cathepsin-L forms
a tetrahedral hemithioacetal (sp3 hybridization) with the β-aldehyde group of the glyoxal
inhibitor.
Figure 3.8. Comparison of the geometries of hemithioacetal formed in inhibitor 1 with
the thioester formed with inhibitor 2.
Several inhibitor complexes of papain with peptide aldehyde inhibitors have been
previously studied by crystallography and NMR. In these complexes, the hemiacetal
complexed with peptide aldehyde inhibitors in complex with papain can exist in two
conformations – (1) the oxygen atom of the hemiacetal is in the oxyanion hole or (2) is in
hydrogen bonding distance of the catalytic site Histidine residue. This has also been
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observed in the case of chymostatin-Streptomyces griseus protease A complex (Delbaere
& and Brayer, 1985) and leupeptin-trypsin complex (Ortiz et al, 1991). In the present
study, we find that the hydrated β-aldehyde is in hydrogen bonding distance of His163
instead of the oxyanion hole. However the presence of an alternative conformation is yet
to be verified.
3.4 Conclusion: We have solved the crystal structures of two covalent inhibitors in
complex with mature Cathepsin L up to resolutions of 2.2 and 1.7Å respectively. These
two classes of inhibitors have identical peptide sequences but different reactive groups.
These were chosen to explore the binding mode of these inhibitors. Both the inhibitors
showed identical binding conformations with respect to S2 and S3 pockets whereas
notable differences observed in the S1 subsite. The glyoxal inhibitor formed a tetrahedral
hemithioketal whereas the diazaomethyl ketone inhibitor formed a thioester bond with
trigonal geometry. The carbonyl oxygen of the β aldehyde group forms a hydrogen bond
with the catalytic His163 while the diazomethylketone is found to have its carbonyl
oxygen facing the oxyanion hole, forming a hydrogen bond with Gln19. The large
differences in the binding mode of the two inhibitors could be attributed to the reactive
groups of these inhibitors. The glyoxal inhibitor is reversible due to its hydrolytically
labile binding whereas the diazomethylketone is an irreversible inhibitor which has a
comparitively slower reaction with the active site thiol. Cathepsin L displays a typical




Structural basis for a non-classical Kazal-type serine
protease inhibitor in regulating host-pathogen
interaction via a dual-inhibition mechanism
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4.1 Introduction
Serine proteases play an important immunomodulatory role in host-pathogen
interactions. Invertebrates lack an adaptive immune system which recognizes and
remembers specific pathogens (Jiravanichpaisal et al, 2006). As an evolutionarily
ancient defense strategy, the innate immune system responds instantaneously to invading
pathogens in a non-specific manner. The innate immune system in the horseshoe crab
comprises of serine protease cascades like the blood coagulation system, melanization
and complement system (Theopold et al, 2004). Horseshoe crab hemocytes contain
granules filled with several serine protease zymogens. Upon mechanical injury or
pathogen invasion, the granules are released into the extracellular milieu by exocytosis,
and clotting enzymes in their precursor forms are activated by a serine protease cascade
triggered by bacterial endotoxin (Armstrong, 2001; Ding et al, 1993). Several serine
protease zymogens including procolotting enzymes, Factor B and Factor C are associated
with the hemolymph coagulation system. The subsequent formation of the coagulation
plug prevents further entry of pathogens (Cerenius and Söderhäll, 2004; Ding & Ho,
2001).
A large number of Kazal-type serine protease inhibitors are expressed in
hemocytes with different specificities against different proteases that target different
microorganisms (Iwanaga & Kawabata, 1998). They are potent inhibitors of serine
proteases like trypsin, α-chymotrypsin, elastase, subtilisin and other bacterial and fungal
proteases, which belong to α2-macroglobulins. These low molecular weight inhibitors
belonging to the Kunitz family of proteinase inhibitors use a lock-and-key mechanism
with their flexible reactive site loops, to mechanistically bind the active-sites of the target
130
proteases (Kanost, 1999). It is speculated that these inhibitors might participate in the
regulation of the hemolymph coagulation cascade (Jiang et al, 2009; Ding et al, 2004)
During our recent work on subtractive ESTs from horseshoe crab infected with
Pseudomonas aeruginosa, two isoforms of Kazal-type inhibitor, CrSPI, each of 9.3 kDa
were discovered (Jiang et al, 2009). The CrSPI-1 and CrSPI-2 (GenBank Accession
numbers: DQ090491 and DQ090492, respectively) isoforms share 97% sequence
identity. Both isoforms are biochemically active. CrSPI-1 inhibits microbial proteases
such as, subtilisin A and protease K. However it is more specific towards subtilisin with
Ki = 1.4nM.
Serine protease inhibitors in plasma are known to perform dual functions of (i)
regulating the activity of endogenous serine proteases, and (ii) inhibiting microbial serine
proteases as a form of host immune defense against the invading pathogen (Hiemstra et
al, 2002). For instance, the human lympho-epithelial Kazal-type inhibitor (LEKTI) plays
an important role in the epithelial tissue homeostasis by regulation of trypsin, and
dysfunction of LEKTI is implicated in Netherton syndrome (Chavanas et al, 2000).
Further, the horseshoe crab Limulus serpins LICI-1, LICI-2 and LICI-3 are known to
regulate serine proteases in the pathogen-induced coagulation cascade (Muta and
Iwanaga, 1996).
The Kazal family is one among 18 families of serine protease inhibitors. Since the
1980’s structures of several members of this family have been reported (Bode and Huber,
1992). The Kazal family is mainly divided into two groups- the classical and the
nonclassical inhibitors. Positions of the cysteine residues that form the disulphide bonds
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differ among classical and non-classical Kazal-type inhibitors. The classical group is
composed of pancreatic secretory trypsin inhibitor, and the ovomucoids.
Both domains 1 and 2 of CrSPI-1 share sequence homology with the non-classical
group I Kazal inhibitors. The characteristic feature of this group is the formation of the
disulfide bond between the first and fifth cysteine residues which are shifted towards the
C-terminus in comparison to the respective residues of a classical Kazal inhibitor like
OMTKY3(Turkey ovomucoid third domain) or OMSVP3 from the silver pheasant(Fig
4.1). Other representatives of this non-classical group are Anemonia Elastase inhibitor,
Crayfish inhibitor(Johansson et al, 1994), Ciona trypsin inhibitor(Odum et al, 1999) and
Galleria trypsin inhibitor from the greater wax moth Galleria mellonella (Nirmala et al,
2001).
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Figure 4.1. Alignment of amino acid sequences of non-classical group I Kazal-type
inhibitors AEI, CrSPI-1 domain I, domain II and a selected classical Kazal-type inhibitor
OMSVP3. The sequences were aligned using CLUSTAL-W. The reactive site is denoted
with an arrow. Disulfide bonds are linked as follows: α-β, II-IV, and III-VI for the non
classical group I inhibitors and I-V, II-IV, and III-VI for the classical inhibitors. In
nonclassical group II inhibitor family, there is an additional disulphide bridge between α
and β half cystines.
133
Hitherto, no crystal structure has been reported for a protease inhibitor from the blood of
arthropods. Furthermore, no crystal structures are available for the non-classical group I
Kazal-type inhibitors. The only available three-dimensional structure in this group is the
solution structure of Anemonia elastase inhibitor (Hemmi et al, 2005). In this chapter,
we report the crystal structure of a double headed non-classical Kazal-type group I
inhibitor CrSPI-1 in complex with its cognate protease, subtilisin, at a ratio of 1:2 and
refined upto 2.6Å resolution. One CrSPI-1 molecule binds two subtilisin molecules. The
reactive site loops of both domains of CrSPI-1 occupy the substrate binding pockets of
subtilisin. Further, based on our structural and biophysical interaction studies, we propose
that domain-2 of CrSPI-1 is a more specific and potent inhibitor for subtilisin, whereas
domain-1 is likely to interact with Furin, a subtilisin homolog, from the host. Thus
CrSPI-1 may act as a regulatory ON/OFF switch in modulating antimicrobial activities
while maintaining homeostasis of host proteases. The present studies on CrSPI-1
provide new insight in the area of host-pathogen interactions in the innate immune
system of the living fossil, C. rotundicauda.
4.2 Experimental
4.2. 1 Expression, purification, crystallization and structure determination
The CrSPI-1 gene was cloned and expressed with pET32-EkLIC system
(Novagen) using the following primers -Forward:5' ACG GAC GAC GAC AAG ATG
TGT CCT CAT ACT TAC AAA 3', Reverse:5' ACG GAG GAG AAG CCC GGT TTA
CAA GCA AGC TTC TAG TGG 3' and expressed in E. coli. The expressed protein
contained a thioredoxin tag, a His-tag and an enterokinase cleavage site. The recombinant
CrSPI, henceforth referred to as rCrSPI-1 fusion protein, was overexpressed at 37 °C
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from a single colony picked from an agar plate. The culture was induced with 300 mM
isopropyl 1-thio-D-galactopyranoside for 4 h to an OD600nm of 0.6. The cells were then
harvested and sonicated. The protein was purified using Nickel-NTA affinity beads
(Qiagen) with PBS (Phosphate Buffered Saline), pH 7.4, 10 mM β-mercaptoethanol,
(BME). The protein was eluted in 300 mM imidazole. The thioredoxin tag was cleaved
by 2-h incubation with enterokinase (Sigma). The complex was prepared by mixing
rCrSPI-1 with subtilisin (obtained from Sigma) in a molar ratio of 1.2:1 (inhibitor:
enzyme) and incubated for 1 hour at 37° C. The complex was then passed through a
Superdex-200 gel filtration column, and fractions were pooled and concentrated upto 20
mg/ml. The crystallization screens were carried out using the hanging drop vapor
diffusion method with Hampton Research Crystal Screen kits I and II and JB Screens
(Jena BioScience, Germany) at room temperature. The initial crystallization conditions
were further optimized using a grid screen by varying the concentration of precipitant.
Plate-like diffraction quality crystals were obtained from 11% (w/v) Polyethylene Glycol
20000 in 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) at pH 6.5. The
crystallization solution was supplemented with 25% glycerol which acts as a cryo-
protectant. A complete data set was collected in the X29-A synchrotron beamline at
Brookhaven National Laboratories, USA. The data collection and refinement statistics are
provided in Table 4.1.
4.2.2 Structure Solution and Refinement
The structure of rCrSPI-1 - subtilisin complex was solved by molecular
replacement method with Molrep (Vagin & Teplyakov, 1997) using the subtilisin
Carlsberg coordinates (PDB code 1SCA). The initial R-factor was 47% and subsequent
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refinement was performed with Refmac (Murshudov et al, 1997) and CNS (Brunger et al,
1998). Strict noncrystallographic symmetry (NCS) was used for subtilisin molecules
during the refinement in CNS. At the stage the R-factors were close to 40, the calculated
electron density map allowed us to build the rCrSPI-1 molecule. Several cycles of
refinements in CNS alternated with model building for the inhibitor complex was carried
out using the program O (Jones et al, 1991) and Coot (Emsley & Cowtan, 2004). The
overall geometry of final model was analyzed by PROCHECK ( Laskowski et al, 1993)
(Table 4.1). Figures 4.2a and 4.2b show the final 2Fo-Fc electron density map of the
reactive site loop region (RSL) of both domains.
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Figure 4.2a. Stereo view of 2Fo-Fc map for the reactive site loop (RSL) region of
domain-1 and of rCrSPI-1 bound to subtilisin contoured at a level of 1σ. The figure was
prepared by using PyMol (DeLano Scientific, Palo Alto, CA).
Figure 4.2b. Stereo view of 2Fo-Fc map for the reactive site loop (RSL) region of
domain-2 of rCrSPI-1 bound to subtilisin contoured at a level of 1σ. The figure was
prepared by using PyMol (DeLano Scientific, Palo Alto, CA).
4.2.3 Isothermal Titration Calorimetry (ITC)
ITC studies were performed using a MicroCal VP-ITC instrument. The rCrSPI-1 at a
concentration of 0.2 mM in PBS pH 7.4, 10 mM BME and subtilisin in the sample cell at
a concentration of 0.012 mM. All experiments were performed at 37°C. rCrSPI-1 was
titrated into subtilisin in 18 injections; each injection consisting of 2 μL of ligand
137
solution. Samples were degassed prior to use. Due to dilution across the needle during
equilibration, the initial peak was discarded. Data analysis was performed using the
MicroCal Origin software. A model considering a stoichiometry 1:2 CrSPI-1: Subtilisin
was considered.
4.2.4 Inhibition of Furin by CrSPI-1
rCrSPI-1 at various concentrations (0.9, 6.3, 8.9, 11.1 and 13.5 nM) was
incubated with 0.02 Unit of Furin (obtained from Sigma) for 60 min at 37°C in 100 µl of
reaction buffer (0.1 M Hepes pH 7.5, 1mM BME and 0.1% Triton X-100). After
incubation, (100 µM) Pyroglutamic acid-Arg-Thr-Lys-Arg-AMC, (Calbiochem), a Furin-
specific fluorogenic substrate was added to the incubated samples following the protocol
by Dufour et al., 1998. Fluorescence readings were measured at after 8, 3, 5, 9 and 24hrs
by taking 10 µl from the reaction mixture and diluting it to 2ml in a cuvette with the
buffer in a Perkin Elmer spectrometer at 437nm wavelength while excitation was at
380nm. The control consisted of Furin and substrate without the inhibitor. The
fluorescence emitted by the fluorogenic substrate and rCrSPI-1 was also measured
simultaneously and the background fluorescence was subtracted later.
4.3 Results and Discussion
4.3.1 Overall structure
The structure of recombinant CrSPI-1 (rCrSPI-1) in complex with subtilisin was
solved by the molecular replacement method from a synchrotron data set. The model was
refined to a final R-factor of 0.21 (Rfree=0.24) at 2.6Å resolution with good
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stereochemical parameters (Table 4.1). The final refined model consists of residues from
Cys1 to Val73 of rCrSPI-1 and Ala1 to Gln274 of subtilisin. The last 10 residues from
the C-terminal of rCrSPI-1 had no interpretable electron density map and were not
modeled. There are three subtilisin and one rCrSPI-1 molecules in the asymmetric unit.
Each rCrSPI-1 molecule interacts with two subtilisin molecules, i.e. domain-1 and
domain-2 of rCrSPI-1 interacts with two independent subtilisin molecules respectively
(Figures 4.3a, 4.3b, 4.3c). The third subtilisin molecule of the asymmetric unit is not in
complex with rCrSPI-1.
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Table 4.1. Crystallographic data and refinement statistics.
Data collection
Unit cell parameters(Å, °) a = 73.84, b = 65.07, c = 111.90










Refinement and quality of model
*Resolution range (Å) 15-2.6
bRwork (%) no. reflections 0.21(24818)
cRfree (%) no. reflections 0.24(1533)
Root mean square deviation
Bond length (Å) 0.009
Bond angle (º) 1.5
Ramachandran plot
Favored region (%) 83.4
Allowed regions (%) 15.3
Generously allowed region (%) 1.4
Disallowed regions (%) 0.0
dAverage B-factors (Å2)
Main chain atoms 37.396
Side chain atoms 37.314
Overall protein atoms (no. atoms) 37.361(6275)
Waters (no. atoms) 35.474 (168)
a Rsym = |Ii -<I>|/ |Ii| where Ii is the intensity of the ith measurement, and <I> is
the mean intensity for that reflection.
b Rwork = | Fobs - Fcalc|/ |Fobs| where Fcalc and Fobs are the calculated and observed
structure factor amplitudes, respectively.
c Rfree = as for Rwork, but for 8.5% of the total reflections chosen at random and
omitted from refinement.
d Individual B-factor refinement were carried out.
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* Reflections greater than I>cI where used in the refinement
Figure 4.3a. Structure of the rCrSPI-1-(Subtilisin) 2 complex. Subtilisin molecules are
drawn in blue and green color and two domains of rCrSPI-1 are in magenta and yellow
color. This figure was prepared by using Molscript(Kraulis, 1991)
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Figure 4.3b. Shows the CrSPI-1: Subtilisin complex. CrSPI-1 is in ribbon representation
and subtilisin is in surface representation.
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Figure 4.3c. Shows the CrSPI-1: Subtilisin complex. CrSPI-1 in surface representation
and subtilisin is in ribbon representation. This figure was prepared by using PyMol.
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The conformation of subtilisin molecules in the complex is similar to that seen in the apo
subtilisin Carlsberg (EC 3.4.21.62) structure and / or in complex with small ligands (Stoll
et al, 1998, Bode et al, 1987; Schmitke et al, 1998), and therefore we will not describe the
structure in detail but provide only a general overview. The structure consists of a central
seven-stranded parallel β-sheet with two α-helices on one side and, a group of four α -
helices on the other side of the central β-sheet. The catalytic triad Ser220, His64 and
Asp32 are located in the substrate binding cleft. The three subtilisin molecules of the
asymmetric unit are identical with an rmsd of 0.1Å in a pairwise superposition of 274 Cα
atoms.
Structure of CrSPI-1
rCrSPI-1 was found to exist as a mixture of both monomers and dimers in
solution as determined by gel filtration, native-PAGE and Dynamic Light Scattering
experiments (DLS). rCrSPI-1 molecule comprises of two domains: domain-1 from Cys1
to Glu40 and domain-2 from Leu41 to Leu83. Both domains adopt similar secondary
structures (domain-1 β1↑β2↓α1β3↑ and domain-2 β4↑β5↓α2). The presence of a central
α-helix α1 (Glu18–Ala24) in the domain-1 and the α2 (Arg63-Ser68) in the domain-2,
and an antiparallel β-sheet in each domain is characteristic of the classical Kazal-type
inhibitors. However, it also shows features of a non-classical Kazal-type serine protease
inhibitor in that rCrSPI-1 harbors an unusual pattern of conserved cysteines. There are
two intra-domain disulphide bridges in domain-1 (Cys1-Cys19 and Cys8-Cys35) and
three in domain-2 (Cys41-Cys70, Cys45-Cys64 and Cys53-Cys82) (Figure 4.3d).
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Figure 4.3d. Cα trace of rCrSPI-1. The disulphide bonds are shown in thick lines along
with the residue numbers. Domain-1 is in magenta and domain-2 is in yellow color. The
approximate location of the missing residues (residues 74 to 81) is shown as doted line.
These figures were prepared by using PyMol. Using BLAST search, the sequence
identities between rCrSPI-1 and the most homologous member of the Kazal family of
inhibitors were analyzed. The observed pattern of S-S bridges in rCrSPI-1 was similar to
the non-classical Kazal-type group 1 inhibitors from sea anemone and crayfish than the
mammalian and avian inhibitors (Figure 4.4).
Figure 4.4. Multiple sequence alignment for the representative members of Kazal-type
Non classical group I proteinase inhibitors. Secondary structural elements are shown
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above the sequences. Conserved residues are shaded in red and yellow boxes. The
reactive site loop residues of P4-P2’ are represented in a green box. The reactive site
residue P1 is shown using an upward pointing magenta arrow. This figure was prepared
by the program Espript (Gouet, 1999)
A search for topologically similar proteins within the PDB database was
performed with the DALI program (Holm & Sander, 1991). The full length rCrSPI-1 did
not find any structural homologs. However the DALI search with individual domains
shows significant similarity with several Kazal-type inhibitors. The DALI search for
domain-1 (residues Cys1 – Glu40) against the pdb database revealed the highest
structural similarities with leech-derived tryptase inhibitor (pdb code 1ldt) yielding an
rmsd of 2.0Å for 38 Cα atoms with 30% sequence identity. This is followed by dipetalin
a Kazal-type thrombin inhibitor (rmsd=2.0Å for 37 Cα atoms; 27% identity; pdb code
1kma) and the insect derived double domain Kazal inhibitor rhodniin, a highly specific
thrombin inhibitor (rmsd=1.5Å for 36 Cα atoms; 35% identity; pdb code 1tbq). Similarly
the structural homology search for domain-2 (Leu41-Leu83) shows several hits with
Kazal-type inhibitors. Domain-2 shares highest structural homolog with turkey
ovomucoid third domain (OMTKY3), a subtilisin inhibitor (pdb code 1yu6), gave an
rmsd of 2.3Å for 32 Cα atoms with 25% sequence identity. This is followed by the
thrombin inhibitor rhodniin (rmsd=2.3Å for 31 Cα atoms; 8% identity; pdb code 1tbq)
and leech-derived tryptase inhibitor (pdb code 1an1) yielding an rmsd of 2.4Å for 29 Cα
atoms with 20% sequence identity. To our knowledge most of the structurally known
Kazal-type inhibitors contains single domain except for rhodniin. Rhodniin is the only
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structurally characterized Kazal-type inhibitor with two domains in complex with
thrombin (1:1 ratio). Both rCrSPI-1 domains show significant structural similarities with
the two domains of rhodniin. However the full length rCrSPI-1 could not be
superimposed with full length rhodniin. This indicates the difference in relative
orientation of the two domains.
The superposition of rCrSPI-1 domain-1 and -2 reveals that their core regions are
similar with 24 Cα atoms having an rmsd of 3.9Å (Figure 4.3). The sequence alignment
shows 27% identical (42% similar) residues between the two domains which includes the
highly conserved cysteines (Figure 4.5a). The preservation of the highly conserved S-S
bridges maintains the architecture of these domains. The overall fold similarity of these
two domains together with the structural homology with other Kazal-type inhibitors
suggests that all Kazal-type inhibitors evolved from a common ancestral gene via
duplication while maintaining diverge amino acid sequences. A study by Merckel et al.,
(2005; Mol Cell 18; 161-170) showed that the similarities between the tertiary structures
are the indicators of gene duplication.
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Figure 4.5a. Stereo view of the Cα superposition of domain-1 (magenta) and domain-2
(yellow) of rCrSPI-1. These two domains superimpose with an rmsd of 3.9Å for 24 Cα
atoms. The superposition was carried out using DALI (Holm & Sander, 1991). This
figure was prepared by using PyMol.
4.3.2 rCrSPI-1: subtilisin complex
rCrSPI-1: subtilisin complex is a heterotrimer in solution, confirmed by gel
filtration, non-reducing SDS-PAGE and Dynamic Light Scattering (DLS) experiments
(Figures 4.5b and 4.5c). This is consistent with the observation of a heterotrimer (1:2
ratio of rCrSPI-1: subtilisin) in the asymmetric unit of the crystal (Figure 4.1). Both
domains of rCrSPI-1 act as two heads to bind with two individual subtilisin molecules.
Our earlier work showed that a truncated domain-1 construct of rCrSPI, was not reactive
to subtilisin, whereas domain-2 showed high affinity for subtilisin, at a Ki of 2.6 nM
(Jiang et al, 2009). However, the structural studies revealed that although both domains
indeed bind to subtilisin, only the domain-2 shows tight interactions with subtilisin. The
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Figure 4.5b. Gel filtration profile of the CrSPI-1 Subtilisin complex together with
subtilisin as a control run on a Superdex 75 column.
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two subtilisin molecules are bound at opposite ends of the elongated inhibitor molecule
forming a ternary complex. Apo subtilisin is a monomer in solution; upon formation of a
complex with rCrSPI-1, it becomes a heterotrimer. Similar complex formation has been
documented for rhodniin, a double domain non classical group II Kazal-type inhibitor
from the blood sucking insect Rhodnius prolixus, which inhibits thrombin via one domain
binding at the active site and the other domain binding the exosite (van de Locht et al,
1995). Similarly a tomato inhibitor belonging to the potato II inhibitor family, a
completely different family of serine protease inhibitors; specifically inhibits (Ki=9nM)
two subtilisin molecules (Barrette-Ng et al, 2003). The present study on rCrSPI-1:
subtilisin heterotrimer complex is the first of this kind for the Kazal-type inhibitors which
employs a dual-inhibition mechanism to engage two protease molecules with different
specificity.
4.3.3 CrSPI-1 RSL interactions with subtilisin
The reactive-site loop (RSL) (Cys1 to Lys6) of domain-1 of rCrSPI-1 binds at the
active site region of subtilisin from P3 (Cys1) to P3’ (Lys6) in a substrate-like manner
(Figure 4.4a). The reactive site residues are well defined in the electron density map
(Figure 4.4c). There are 11 hydrogen bonding contacts between domain-1 RSL and
subtilisin. Of these 5 of them are sidechains mediated hydrogen bonding contacts. The
mainchain amide group of P1 residue His3 is involved in hydrogen bonding contact with
Oγ of the catalytic Ser220 (2.63Å). The carbonyl O atom of the P1 His3 interacts with
backbone amide Nitrogen of active site Ser220 and Nγ2 of Asn154 of subtilisin (Table
4.2).
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In Kazal-type inhibitors, the P1 residue is the most exposed residue and makes
approximately 50% of the hydrogen bonding interactions with the protease active site
residues. (Kleanthous, 2000; Maynes et al, 2005). In the subtilisin-rCrSPI-1 complex,
domain-1 P1
Table 4.2. Selected hydrogen bonding contacts between rCrSPI-1 domain-1 and
subtilisin
Site CrSPI1 Subtilisin Distance (Å)
P3 Cys D2 N Gly A126 O 3.14
Cys D2 O Gly A126 N 2.88
P1 His D4 N Ser A220 Oγ 2.63
His D4 Nδ1 Asn A154 Nδ2 3.03
His D4 O Asn A154 Nδ2 2.66
His D4 O Ser A220 N 3.28
His D4 O Ser A220 Oγ 2.92
P1’ Thr D5 N Ser A 220 Oγ 3.34
P2’ Tyr D6 N Asn A217 O 2.65
Asp D18 Oδ1 Asn A154 O 2.86
Asp D18 Oδ2 Asn A154 O 2.54
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residue His3 contributes 5 hydrogen bonding contacts (or 45% of the total hydrogen
bonding interactions) with subtilisin (Figure 4.6a). Pro2 occupies the P2 position and
having hydrophobic interactions with subtilisin. In most of the canonical serine
proteinase inhibitors the P3 residue is engaged in a disulphide bond. In rCrSPI-1 Cys1 is
in P3 position is engaged in a disulphide bond with Cys19 and part of the hydrophobic
core which consists of Leu125 (subtilisin) and Pro2 (rCrSPI-1). Thr4 is in the P1’
position along with Tyr5 and Lys6 are in P2’ and P3’ positions respectively. P2’ residue
Tyr5 maintains stacking interactions with Phe188 of subtilisin.
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Figure 4.6a. Stereo view of the interactions between subtilisin (cyan) and the reactive
site loop of domain-1 (magenta). In domain-2 of rCrSPI-1 Glu48 takes the position of
His3 in the P1 pocket of domain-1 and makes 10 out of 13 total hydrogen bonding
contacts with subtilisin (Fig 4.6b). The remaining hydrogen bonding contacts with
subtilisin are from P1’ Glu49, P2’ Tyr50 and P4 Val45 of domain-2 respectively (Table
4.3). Similar to the P2’ residue Tyr5 of domain-1, Tyr50 takes the P2’ position in
domain-2 and maintains stacking interactions with Phe188 of subtilisin. In addition P3
residue Cys46 mediates hydrophobic
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Table 4.3. Selected interactions between rCrSPI-1 domain-2 and subtilisin
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interactions with the side chain Leu125 of subtilisin. Overall RSL interactions in domain-
2 clearly indicate that the P1 residue Glu48 is the primary mediator of interactions with
subtilisin. These observation combined with the binding affinities of both domains with
subtilisin suggests that domain-2 is more preferred to interact tighter with subtilisin than
domain-1.
Figure 4.6b. Stereo view of the interactions between subtilisin and the reactive site loop
of domain-2.
Table 4.4 show the P3 to P3’ residues of RSLs of various substrates-like binding
serine protease inhibitors such as for subtilisin, thrombin and Furin. It is evident that
subtilisin prefers Glu in the P1 position of the Kazal-type inhibitors and the Furin
inhibitors hold a basic residue. In addition to the highly conserved P3 position Cys, P2’
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position is taken by a hydrophobic sidechain. Further the P1 position is relatively
variable and it determines the specificity of the proteases. Specific interactions between
the RSLs of rCrSPI-1 and subtilisin are schematically illustrated in supplementary Figure
4.3.
Table 4.4. Reactive site loop regions from P3 to P3’ position of selected serine protease
inhibitors
Inhibitors P3 P2 P1 P1’ P2’ P3’
CrSPI-1 domain-1 Cys1 Pro2 His3 Thr4 Tyr5 Lys6
CrSPI-1 domain-2 Cys46 Thr47 Glu48 Glu49 Tyr50 Asp51
OMTKY3 Cys16 Thr17 Leu18 Glu19 Tyr20 Arg21
Eglin C Asn117 Gly118 Met119 Asp120 Val121 Ile122
Tomato inhibitor II dom-1 Cys3 Thr4 Arg5 Glu6 Cys7 Gly8
Tomato inhibitor II dom-2 Cys60 Thr61 Phe62 Asn63 Cys64 Asp65
Rhodniin domain-1 Cys8 Pro9 His10 Ala11 Leu12 Arg13
Rhodniin Cys60 domain-2 Asp61 Gly62 Asp63 Glu64 Tyr65 Lys66
Spn4A (Furin inhibitor
from Drosophila)
Arg350 Lys351 Arg352 Ala353 Ile354 Met355
Human PI8( Furin
Inhibitor)
Asn337 Ser338 Arg339 Cys340 Ser341 Arg342
Note: Subtilisin inhibitors: CrSPI-1 domain-2; Tomato inhibitor II (domain-1 and
domain-2); OMTKY3 and Eglin C. Thrombin inhibitor: Rhodniin inhibitor. Furin
inhibitor: Spn4A from Drosophila melanogaster, Human Protease Inhibitor 8 and CrSPI-
1 domain-1 (annotated).
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4.3.4 Rigidity of the RSL
The conformation adopted by the reactive site loops (RSLs) of both domains of
rCrSPI-1 is similar. They superimposed with an rmsd of 0.80Å for the residues from
position P3 to P3’ (Figure 4.7a). The RSL conformation in several families of serine
proteinase inhibitors, in many complexes and in different crystal environments adopts a
similar conformation. Similar to other members of the Kazal family of inhibitors, the
disulfide bonds formed by cysteine residues at the P3 and P5’ positions (Cys1 and Cys8
in domain-1 and Cys46 and Cys54 in domain-2) of CrSPI-1 may hold the RSL in a
relatively rigid conformation.
The RSLs backbone torsion angles (ψ/φ angles) of rCrSPI-1 is similar to each
other and compares with other proteinase inhibitors such as OMTKY3 and Eglin-C
complex with subtilisin (Table 4.5). In addition, the RSLs backbone torsion angles of
rCrSPI-1 are similar to several structurally unrelated serine protease inhibitors complexes
and confirm the canonical binding mode for rCrSPI-1 (Supplementary Table 4.4; Figure
4.7b).
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Table 4.5. Main chain torsion angles of the reactive site loops of serine protease















P4 - -171/-63 -101/140 -71/140
P3 -126/163 61/167 -132/156 -138/168
P2 -76/156 -131/167 -62/161 -62/143
P1 -100/46 -131/40 -106/36 -115/44
P1’ -82/146 -91/133 -77/134 -96/168
P2’ -101/88 -82/100 -96/106 -117/109
P3’ -122/71 -138/68 -142/74 -121/112
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Figure 4.7a. Conformations of the reactive site loop (RSL) of domain-1 (magenta) and
domain-2 (yellow) bound to subtilisin
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Figure 4.7b. Superposition of the reactive site loops of domain-1, domain-2, Eglin C
(gray) and OMTKY3 (cyan). The RSLs are shown in stick representation whereas the
substrate binding site of subtilisin is shown in surface representation. These figures were
generated by using PyMol.
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The superposition of the active site region of subtilisin complexes such as
OMTKY3 and Eglin C with rCrSPI-1: subtilisin heterotrimer complex reveals that
different inhibitor loop sequences can be accommodated in the substrate binding site of
subtilisin with minimal sidechain rearrangement (Figure 4.7b). Further it indicates the
rigid conformation of the RSL of these inhibitors. This is further supported by the fact
that both the mainchain and sidechain groups of subtilisin remain relatively in the same
conformation in several complexes and in apo form. In domain-2, out of three S-S
bridges two of them (Cys41-Cys70 and Cys45-Cys64) are connected with the central α-
helix region, which maintains a rigid conformation for the reactive site loop (RSL) of this
domain than the RSL in domain-1. Notably, the presence of three disulphide bonds in
domain-2 probably explains for its rigidity and makes it specific and potent towards its
particular cognate protease subtilisin. It is worth mentioning here that in the case of
OMSVP3 in which introducing an additional disulphide bridge made it specific to only
one protease α-chymotrypsin and lost its inhibition for other proteases (Hemmi et al,
2003).
In addition to the S-S bridges, there are three important internal hydrogen bonds
which aid maintaining the rigidity of the RSL in CrSPI-1. These hydrogen bonds in
domain-1 are (1) P2-P1’ hydrogen bond between the carbonyl oxygen of Pro2 and amide
nitrogen of Thr4 of the reactive site loop, (2) hydrogen bonding between Asn18 and
Phe21, and (3) the Nδ2 of Asn18 interacts with the mainchain carbonyl atoms of Pro2
and Thr4 at the P2 and P1’ positions of the RSL. Similarly, in domain-2, the interactions
which involved the sidechains from Asn62, Thr47 and Glu49 may aid to maintain the
rigidity of the RSL. The interactions between Thr47 and Glu49 are similar to the
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interactions of P2-P1’ of domain-1. Similar interactions are also observed in the
OMTKY3 complexes with several proteases (Maynes et al, 2005;).
In order to reduce the entropic cost of binding the reactive site loops (RSLs) of
Kazal-type inhibitors and in particular, CrSPI-1 is firmly held in a preferred conformation
that is complementary to the substrate binding site of specific proteases. Further a rigid
conformation of the RSL is likely to prevent proteolytic cleavage of the inhibitor upon
interaction with proteases.
4.3.5 Specificity of CrSPI-1 domains
Kazal type serine protease inhibitors usually occur as single or multi-domain
proteins with each domain having a different specificity towards a particular protease
(Somprasong et al, 2006). Although the sequence of the reactive site loop tends to be
highly variable, the specificity for a protease is dictated by the P1 residue. Furin, a
homolog of subtilisin, has specificity towards paired basic residues for cleavage
(Thomas, 2002). Furin cleaves a wide range of proproteins at the consensus sequence -
Arg-Xaa-Lys/Arg-Arg-↓ and the minimal consensus sequence for Furin is -Arg-Xaa-Xaa-
Arg-↓ (Jean, Francois et al). The CrSPI-1 domain-1 RSL consists of two basic residues
(His3 and Lys6). Furin might not cleave this RSL due to its rigid conformation and thus it
may act as an inhibitor for Furin. Notably the Kazal protease inhibitors recognize the
proteases in a substrate-like manner. Several proteins have been engineered to provide a
Furin consensus motif in their reactive site loops and thereby inhibit Furin. For instance,
the Turkey ovomucoid third domain RSL sequence was mutated from Ala-Cys-Thr-
Leu18 to Arg-Cys-Lys-Arg18(Lu et al, 1993), α1- antitrypsin Portland RSL mutated
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from Ala355-Ile-Pro-Met358- to -Arg355-Ile-Pro-Arg358 and both have successfully
inhibited Furin (Jean et al, 1998). These inhibitors mimic highly specific substrates. Due
to the tight binding and specific rigid conformation of the RSL residues, these inhibitors
are able to arrest the enzymatic reaction at the intermediate stage of hydrolysis of the
peptide bond (Radisky et al).
Glu48 is the P1 residue in the RSL of domain-2 and the presence of Glu in P1
position is more specific for subtilisin inhibitors (Somprasong et al, 2006; Odum et al,
1999). Glu48 is well buried in the S1 pocket with 10 hydrogen bonding contacts with
subtilisin compared to His3, the P1 residue of domain-1 which makes only 5 hydrogen
bonding contacts. This suggests that Glu48 in the P1 pocket of domain-2 is more specific
and maintains a tight interaction with subtilisin. In addition the P2 residue of domain-2
makes an additional hydrogen bond with the active site His63 sidechain as compared to
domain-1.
586Å2 surface area of domain-1 of CrSPI-1 is buried upon complex formation
with subtilisin, whereas 592Å2 for domain-2. In particular the reactive site loop residues
of domains-1 and -2 contribute 445Å2 and 529Å2 of buried surface area respectively. This
account for 76% and 89% of each domain’s binding interface with subtilisin. Thus the
RSL of domain-2 contributes a greater buried area compared to the RSL of domain-1.
Notably domain-2 inhibits subtilisin with Ki =2.6nM, whereas no reactivity observed
between domain-1 and subtilisin. Further the ITC experiments reveals that the integration
curve fitted well considering a model in which one CrSPI-1 molecule binds two
Subtilisin molecules (stoichiometry 1:2), with binding sites in CrSPI-1 considered non-
identical and independent with affinities 0.37 and 670 M (Fig 4.8a). This suggests that
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domain-2 of CrSPI-1 most likely binds first to a subtilisin molecule following with
domain-1 binds with a second subtilisin at a lower affinity.
4.4 Isothermal Titration Calorimetry (ITC) binding studies with CrSPI-1
ITC binding studies with tagged CrSPI-1 were carried out using VP-ITC and ITC-200
Calorimeters. The results are in fair agreement. The interaction between thioredoxin
tagged CrSPI-1 and subtilisin is endothermic, therefore, entropically driven. On the other
hand, the interaction of untagged CrSPI-1 is exothermic and with unfavourable entropic
contribution. There is a difference in the thioredoxin tagged and untagged protein binding
kinetics. There is a reduced conformational entropy loss upon binding with the tagged
protein probably, due to the stability provided by the tag CrSPI-1. Thioredoxin tag makes
the enthalpy positive and without tag, the enthalpy is found to be negative. This maybe
because there is a conformational change coupled to binding, and the tag helps in
promoting the binding competent conformation). There are two binding sites for the
CrSPI-1: Subtilisin interaction (1:2). The Hill coefficient for the binding is 0.3-0.4. The
two binding sites in CrSPI-1 could presumably be non-identical and independent,
identical with negative cooperativity or non-identical with negative cooperativity.
Considering that CrSPI-1 is not a symmetric molecule, the simplest and more plausible
explanation is that two binding sites are non-identical and independent. The two binding
sites show significantly different affinities: k1 =2x106 M-1, k2 = 2x104 M-1 and binding
enthalpies: dh1 = 40 kcal/mol, 6 kcal/mol. The model used for the analysis is a general
model with two binding sites in CrSPI-1. The titrations correspond to reverse titrations,
where the macromolecule with two binding sites is placed in the injection syringe. This is
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the reason for the unusual look of the titrations: during the first injections CrSPI-1 is in an
excess of Subtilisin inside the calorimetric cell and, therefore, both binding sites are
occupied; as the titration proceeds, CrSPI-1 increases concentration and free Subtilisin
decreases in concentration and Subtilisin dissociates from low affinity binding sites
(accompanied by a negative enthalpic contribution).
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Figure 4.8a. Isothermal Titration Calorimetric (ITC) curve for rCrSPI-1 titrated against
subtilisin at 37°C. Each peak represents the injection of rCrSPI-1 0.2 mM into the ITC
cell containing subtilisin 0.012 mM, in buffer PBS pH 7.4, 10 mM BME. A sequence of
18 injections, each injection consisting of 2 μL of ligand solution, was performed. The
experimental data were fitted considering a model in which CrSPI-1 binds two Subtilisin
molecules, and the two binding sites in CrSPI-1 are non-identical and independent.
Binding association constants of 2.7x106 M-1 and 1x103 M-1 were obtained from non-
linear regression analysis, corresponding to dissociation constants of 0.37 and 670 M,
respectively.
166
Figure 4.8b. Isothermal Titration Calorimetric (ITC) curve and binding parameters for
rCrSPI-1 titrated against subtilisin. The experiment was carried out on a Microcal iTC-
200 calorimeter.
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ITC studies with peptide derived from CrSPI-1 domain 2
We have studied the interactions of various peptides derived from RSL regions of both
domains of rCrSPI-1 using ITC experiments (Figure 4.9a, 4.9b). The interaction between
the peptide VCTEEY derived from domain 2 reactive site loop and Subtilisin shows a 1:1
stoichiometry (one binding site). The binding affinity is low (k = 1.5x103 M-1), which is
lower than that of the low affinity binding site of CrSPI-1 domain 1 of 2x104 M-1.
Figure 4.9a. Isothermal Titration Calorimetric (ITC) curve and binding parameters for
VCTEEY titrated against subtilisin. The experiment was carried out on a Microcal iTC-
200 calorimeter.
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Figure 4.9b. Isothermal Titration Calorimetric (ITC) curve and binding parameters for
VCTEEY titrated against subtilisin. The experiment was carried out on a Microcal iTC-
200 calorimeter.
Several Kazal-type inhibitors with Glu in the P1 site are known to inhibit
subtilisin. For instance, the five domain shrimp Kazal inhibitor SPIPm2 – with two
subtilisin inhibiting domains having P1 Glu residues (Somprasong et al, 2006), EPI1, a
Kazal-Like Protease Inhibitor from Phytophthora infestans (Miaoying Tian et al, 2005 )
has P1 Glu residue. But so far, no Kazal inhibitor of subtilisin has been known to have a
His residue in the P1 site. Further His residue in P1 site is very rare among all the Kazal
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inhibitors discovered so far. This leads us to believe that domain-1 may not be a subtilisin
specific inhibitor and instead be responsible for Furin inhibition. The presence of two
basic residues in the RSL of domain-1 is most likely the key residues for inhibition of
Furin in a substrate-like manner. It must be noted that this model needs to be further
tested for validation. These two domains of CrSPI-1 could have been a product of gene
duplication to generate a dual specificity inhibitor with one domain functioning as an
inhibitor of host proprotein converting subtilisin-like enzyme CrFurin and the other
domain functioning as a pathogen specific protease, subtilisin inhibitor.
4.5 Implications for the possible dual functions of CrSPI-1
The preference of CrSPI for microbial protease, subtilisin suggests that this
isoform targets serine proteases of the invading microbes. In fact, subtilisin is the
virulence factor used by various pathogens or parasites to gain entry into the host cells
during infection. Besides direct suppression of the microbial proteases, CrSPI-1 was
shown to immunomodulate the host through its interaction with the host target, CrFurin
(Jiang et al, 2009). CrFurin, a host serine protease which is a homolog of subtilisin-type
serine protease involved in processing multiple immune proproteins. By an ex vivo
inhibition assay using recombinant CrSPI-1 we have demonstrated that CrFurin is the
endogenous cognate protease of CrSPI (Jiang et al., 2009). It was observed that the
transcription profile and the protein activities of CrFurin and CrSPI-1 showed a
reciprocal relationship.
The Furin binding mode of CrSPI-1 was predicted by a comparison with the
complex crystal structure of rCrSPI-1: subtilisin and Furin (Pdb code 1p8j). Furin is a
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Figure 4.10a. Model of Furin-rCrSPI-Subtilisin heterotrimer complex shows Cα
representation of superimposed Furin (in orange color) on subtilisin-rCrSPI complex.
Furin and subtilisin share a sequence identity of 23%. The Furin: CrSPI-1 complex model
was generated by superimposing domain-1 of CrSPI-1: subtilisin complex onto the
structure of Furin (pdb code 1p8j) to yield an rmsd of 2Å for 268 Cα out of 274 Cα atoms
of Subtilisin. The Furin-rCrSPI-1-Subtilisin heterotrimer complex was generated using
the modeled Furin-rCrSPI-1-domain-1 and subtilisin-rCrSPI-1-domain-2 complex crystal
structure.
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homolog of subtilisin and shares a sequence identity of 23% (~40% similarity). Moreover
the structure of subtilisin superimposes with subtilisin-like domain of Furin with an rmsd
of 2Å for 268 Cα atoms out of 274 Cα atoms of subtilisin. The domain-1 CrSPI-1:
subtilisin complex was superimposed onto the structure of Furin (pdb code 1p8j) and
copied the coordinates of CrSPI-1 to Furin (Figure 4.8). The RSL region from P3 (Cys1)
to P3’ (Lys6) occupies the substrate binging site of Furin. In addition compared to the
binding of subtilisin with CrSPI-1-domain-1, the Furin-CrSPI-1 domain-1 reveals several
additional interactions between Furin and domain-1 (Figure 4.8). The reactive site loop
residues of domain 1 of CrSPI-1 spanning P3 to P3’ are accommodated well in the active
site cleft of Furin. Similar to a typical Furin inhibitor Arg in the P1 position, the P1
residue His 3 side chain extends into the S1 pocket of the active site and is in close
proximity of the nucleophilic Ser368 of Furin. The second basic residue P3’ Lys is found
in the active site cleft close to the S2’ subsite of Furin. The presence of these two basic
residues in the negatively charged cleft of Furin could explain the potential inhibitory
activity of CrSPI-1 against Furin. Further, the superimposition of Subtilisin and Furin
reveals that the catalytic triads of Subtilisin (Ser 220 – His 64 – Asp 32) and Furin (Ser
368 - His 194 - Asp 153) are found to be similar and can be superimposed very well. The
subtilisin-like domain of Furin is very similar to Subtilisin but there are some differences
in the residues forming the active site which may explain the difference in the surface
charge of the active sites of the two proteases (Henrich et al, 2003). Furin has a much
higher negative charge in the active site cleft and hence prefers basic residues.
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Figure 4.10b. Cα trace for the heterotrimer Furin-CrSPI-Subtilisin complex proposed
model.
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Figure 4.10c. Surface representation for Furin and Subtilisin, and ribbon representation
for CrSPI-1 of the heterotrimer model.
Our studies revealed that in comparison to domain-1, the domain-2 comprising of
three S-S bridges enhances the rigidity of the RSL to achieve tight interactions with
subtilisin. Besides, domain-2 posses the most preferred residue Glu in the P1 position of
the Kazal type inhibitors to specifically inhibit subtilisin. While domain-1 has a pair of
basic residues to act as a potential substrate-like binding inhibitor for Furin. It is
important to note that both RSLs are rigid. This rigid conformation is a prerequisite to
resist the proteolytic cleavage of the inhibitor upon interaction with the protease. Thus,
CrSPI regulates serine protease driven antimicrobial defense at the acute phase of
infection while maintaining homeostasis under native condition (Jiang et al, 2009).
CrSPI-1 has been found to inhibit its cognate protease from the host, CrFurin in a dose
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dependent inhibitory assay. It interacts with microbial subtilisins as well as a host
endogenous C3 complement component, p50 which is required for ingestion and
destruction of pathogens. All three proteases are involved in important roles in immune
responses and homeostasis. These studies demonstrate that CrSPI-1 serves several




Conclusions and Future Directions
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5.1 Conclusions
The crystal structures of human cathepsin L complexed with six inhibitors
have been thoroughly described in this thesis. Of these four of them are propeptide
mimetic and two of them are synthetic dipeptidyl complexes. In addition, their inhibition
mechanisms of action were proposed based on these complex crystal structures combined
with molecular dynamics analyses (in the case of propeptide mimite inhibitors). These
propeptide mimetic inhibitors are very potent inhibitors similar to the full length 96aa
propeptide. Similar to propeptides, these propeptide mimetic inhibitors binds in the
reverse direction relative to a substrate and span both the S’ and S subsites of the
cathepsin L active site. These inhibitors have inhibitory constants (Ki) between 20nM
and 500nM. This tight binding facilitated the co-crystallization with the cathepsin L.
Further the mode of inhibition of these series of inhibitors with the cathepsin L
will provide a general strategy for inhibiting other cathepsins as well as other proteases.
Besides, the structural information resulted from this study allowed us to identify the
putative specificity determinants of cathepsin L. This site is specifically located on the S’
subsite which was not explored before. These vital structural implications will be used for
developing highly specific inhibitors of cathepsin L towards drug design for the treatment
of human diseases involving cathepsin L.
As a comparison with the propeptide mimetic reverse binding mode inhibitors this
thesis also reported two crystal structure complexes of cathepsin L covalently bound
inhibitors. These two covalent bound inhibitors bind in the active site in the same
direction as substrates. The two inhibitors have identical peptide sequences but different
reactive groups. These were chosen to explore the binding mode of these inhibitors. Both
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the inhibitors showed identical binding conformations with respect to S2 and S3 pockets
whereas there were some differences in the S1 subsite. The glyoxal inhibitor formed a
tetrahedral hemithioketal whereas the diazaomethyl ketone inhibitor formed a thioester
bond with trigonal geometry. The carbonyl oxygen of the beta aldehyde group forms a
hydrogen bond with the catalytic His 163 while the diazomethylketone is found to have
its carbonyl oxygen facing the oxyanion hole, forming a hydrogen bond with Gln19. The
large differences in the binding mode of the two inhibitors could be attributed to the
reactive groups of these inhibitors. The glyoxal inhibitor is reversible due to its
hydrolytically labile binding whereas the diazomethylketone is an irreversible inhibitor
which has a comparitively slower reaction with the active site thiol. Cathepsin L displays
a typical papain-like architecture and closely resembles Cathepsins S and K. The
structure of human Cathepsin L in complex with these two inhibitors will be important in
the structure-based drug design. These results will lay groundwork for designing the
therapeutically useful inhibitors for Cathepsin L as well as Cathepsins S and K which has
slightly modified S2 and S3 binding pockets.
Similarly in the case of subtilisin: CrSPI-1 complex, interesting structural and
functional features were revealed by the 2.6Å resolution crystal structure. This study
showed how such multidomain inhibitors can simultaneously inhibit multiple enzymes
within a single ternary complex. In addition based on our structural and biophysical
studies we proposed the substrate preference of the two domains of CrSPI-1. I.e. Domain-
2 is more potent and specific towards the bacterial protease subtilisin. Domain-1 is likely
to interact with the host protease, Furin, acting like an “on-off” switch in the regulation of
host’s and pathogen’s proteases. The structure of CrSPI-1-subtilisin ternary complex will
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help to understand the innate immune system at a molecular level. This study on rCrSPI-
1: subtilisin heterotrimer complex is the first of this kind for the Kazal-type inhibitors
which employs a dual-inhibition mechanism to engage with two protease molecules with
different specificity, a hither to unknown mechanism.
5.2 Future directions
1) Cathepsin L: The various Cathepsin structures demonstrate that the difference
in function is attributed to the specific structural features. Crystal structures of
Cathepsins with sophisticated small-molecule inhibitors will be extremely
beneficial in understanding the specificity differences of these enzymes.
Detailed structural information of the target enzyme and the binding mode of
the inhibitor have been shown to yield more potent and selective inhibitors than
combinatorial chemistry techniques. By effectively utilizing the structural
information generated through the present study, a series of structure optimized
next generation inhibitors will be designed towards drug development. Further
the knowledge gained through this study will be expanded to other cathepsin
such as cathepsin S and cathepsin K which share similarities in overall structure
as well as binding pockets S2 and S3 which are slightly modified.
2) CrSPI-1: As a continuation of our studies in subtilisin : CrSPI-1, the Furin
CrSPI-1 complex, particularly the activity of domain-1 of CrSPI-1 with Furin
will be investigated to completely elucidate the ON/OFF swtich mechanism
involving the heterotrimer. In addition CrSPI-2, the isoform of CrSPI-1, will be
structurally characterized. Since CrSPI-2 has specificity for Trypsin, complex
formation will be carried out. The differences in the mode of inhibition of
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CrSPI-1 and CrSPI-2 will be compared in order to understand the differences in
their specificities. Further, along with their cognate protease complexes, the
potential role of domain1 in Furin inhibition will be investigated for CrSPI-2.
These studies will be beneficial for not only understanding enzyme inhibition
but will provide a foundation for developing antipathogenic agents. The
involvement of Furin in the entry of several viral pathogens makes it an
important target for treatment of several infectious diseases like Anthrax and
Pseudomonal infections. The potential role of CrSPI-1 domain 1 in the
inhibition of Furin is currently under progress.
In summary, the inhibition mechanism of cysteine and serine protease such as
Cathepsin L and subtilisin were studied. Both proteases adopts a similar catalytic
triad (example: Subtilisin Asp32-His64-Ser221; Papain Cys25-His159-Asn175) and a
similar oxyanion hole. Moreover many of these proteases are secreted as inactive
forms called zymogens and subsequently activated by proteolysis. The propeptide
mimic inhibitors of Cathepsin L bind non covalently in the active site in a reverse
direction. Further, the study on covalent dipeptidyl inhibitors in complex with
Cathepsin L uncover how they inhibit both reversibly or irreversibly based on the
reactive group of the inhibitor. In addition, the studies on serine protease subtilisin
and its natural proteinaceous inhibitor that binds non-covalently , reveal the inhibition
by a substrate-like conformation of the inhibitor’s reactive site loop. The results
presented in this thesis will lead to the structure based optimization of next generation
inhibitors for therapeutic purposes.
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